1
|
Wu G, Du J, Xu G, Li M, Yu C. Possibility of using the imaged capillary isoelectric method as a multi-attribute method for bispecific antibodies. Electrophoresis 2024. [PMID: 38973474 DOI: 10.1002/elps.202400066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2024] [Revised: 05/09/2024] [Accepted: 05/23/2024] [Indexed: 07/09/2024]
Abstract
An imaged capillary isoelectric focusing (icIEF)-based method was developed and validated as a multi-attribute method for a bispecific antibody (BsAb). First, as the traditional application of the icIEF method, it serves as an identity assay and purity assay for the BsAb. Second, the method can also be used as an impurity assay for the homodimer monoclonal antibodies generated during BsAb assembly. The homodimer impurity analysis for BsAb is usually done by hydrophobic interaction chromatography methods in the industry. The icIEF method has good sensitivity (down to 4 µg/mL in a limit of quantitation) when UV fluorescence detection is used, which detects the native fluorescence of proteins. This is the first report that an icIEF method has been applied as impurity assay.
Collapse
Affiliation(s)
- Gang Wu
- National Institutes for Food and Drug Control, State Key Laboratory of Drug Regulatory Science, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, P. R. China
| | - Jialiang Du
- National Institutes for Food and Drug Control, State Key Laboratory of Drug Regulatory Science, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, P. R. China
| | - Gangling Xu
- National Institutes for Food and Drug Control, State Key Laboratory of Drug Regulatory Science, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, P. R. China
| | - Meng Li
- National Institutes for Food and Drug Control, State Key Laboratory of Drug Regulatory Science, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, P. R. China
| | - Chuanfei Yu
- National Institutes for Food and Drug Control, State Key Laboratory of Drug Regulatory Science, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, P. R. China
| |
Collapse
|
2
|
Xu M, Liu T, Xu J, Guo Q, Ren Y, Zhu W, Zhuang H, Pan Z, Fu R, Zhao X, Wang F, Mao Y, Song L, Song Y, Ji L, Qian W, Hou S, Wang R, Li J, Zhang D, Guo H. Rapid Mass Spectrometry-Based Multiattribute Method for Glycation Analysis with Integrated Afucosylation Detection Capability. JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY 2024. [PMID: 38970800 DOI: 10.1021/jasms.4c00063] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 07/08/2024]
Abstract
The multiattribute method (MAM) has emerged as a powerful tool for simultaneously screening multiple product quality attributes of therapeutic antibodies. One such potential critical quality attribute (CQA) is glycation, a common modification that can impact the heterogeneity, functional activity, and immunogenicity of therapeutic antibodies. However, current methods for monitoring glycation levels in MAM are rare and not sufficiently rapid and accurate. In this study, an improved mass spectrometry (MS)-based MAM was developed to simultaneously monitor glycation and other quality attributes including afucosylation. The method was evaluated using two therapeutic antibodies with different glycosylation site numbers. Treatment with IdeS, Endo F2, and dithiothreitol generated three distinct subunits, and the glycation results obtained were similar to those treated with PNGase F, which is routinely used to release glycans; the sample processing time was greatly reduced while providing additional quality attribute information. The MS-based MAM was also employed to assess the glycation progression following forced glycation in various buffer solutions. A significant increase in oxidation was observed when forced glycation was conducted in an ammonium bicarbonate buffer solution, and a total of 23 potential glycation sites and 4 significantly oxidized sites were identified. Notably, we found that ammonium bicarbonate was found to specifically stimulate oxidation, while glycation had a synergistic effect on oxidation. These findings establish this study as a novel methodology for achieving a technologically advanced platform and concept that enhances the efficacy of product development and quality control, characterized by its broad-spectrum, rapid, and accurate nature.
Collapse
Affiliation(s)
- Mengjiao Xu
- State Key Laboratory of Macromolecular Drugs and Large-Scale Manufacturing, School of Pharmaceutical Sciences, Liaocheng University, Liaocheng 252059, China
- NMPA Key Laboratory for Quality Control of Therapeutic Monoclonal Antibodies, Shanghai 201203, China
| | - Tao Liu
- State Key Laboratory of Macromolecular Drugs and Large-Scale Manufacturing, School of Pharmaceutical Sciences, Liaocheng University, Liaocheng 252059, China
- NMPA Key Laboratory for Quality Control of Therapeutic Monoclonal Antibodies, Shanghai 201203, China
- State Key Laboratory of Macromolecular Drugs and Large-Scale Manufacturing, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, China
- Department of Oncology, Huashan Hospital, Fudan University, Shanghai 200040, China
| | - Jin Xu
- State Key Laboratory of Macromolecular Drugs and Large-Scale Manufacturing, School of Pharmaceutical Sciences, Liaocheng University, Liaocheng 252059, China
- NMPA Key Laboratory for Quality Control of Therapeutic Monoclonal Antibodies, Shanghai 201203, China
- State Key Laboratory of Macromolecular Drugs and Large-Scale Manufacturing, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, China
| | - Qingcheng Guo
- State Key Laboratory of Macromolecular Drugs and Large-Scale Manufacturing, School of Pharmaceutical Sciences, Liaocheng University, Liaocheng 252059, China
- NMPA Key Laboratory for Quality Control of Therapeutic Monoclonal Antibodies, Shanghai 201203, China
- State Key Laboratory of Macromolecular Drugs and Large-Scale Manufacturing, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, China
- Taizhou Mabtech Pharmaceuticals Co., Ltd., Taizhou 225316, China
| | - Yule Ren
- State Key Laboratory of Macromolecular Drugs and Large-Scale Manufacturing, School of Pharmaceutical Sciences, Liaocheng University, Liaocheng 252059, China
- NMPA Key Laboratory for Quality Control of Therapeutic Monoclonal Antibodies, Shanghai 201203, China
| | - Weifan Zhu
- State Key Laboratory of Macromolecular Drugs and Large-Scale Manufacturing, School of Pharmaceutical Sciences, Liaocheng University, Liaocheng 252059, China
- NMPA Key Laboratory for Quality Control of Therapeutic Monoclonal Antibodies, Shanghai 201203, China
| | - Huangzhen Zhuang
- State Key Laboratory of Macromolecular Drugs and Large-Scale Manufacturing, School of Pharmaceutical Sciences, Liaocheng University, Liaocheng 252059, China
- NMPA Key Laboratory for Quality Control of Therapeutic Monoclonal Antibodies, Shanghai 201203, China
| | - Zhiyuan Pan
- State Key Laboratory of Macromolecular Drugs and Large-Scale Manufacturing, School of Pharmaceutical Sciences, Liaocheng University, Liaocheng 252059, China
- NMPA Key Laboratory for Quality Control of Therapeutic Monoclonal Antibodies, Shanghai 201203, China
| | - Rongrong Fu
- State Key Laboratory of Macromolecular Drugs and Large-Scale Manufacturing, School of Pharmaceutical Sciences, Liaocheng University, Liaocheng 252059, China
- NMPA Key Laboratory for Quality Control of Therapeutic Monoclonal Antibodies, Shanghai 201203, China
| | - Xiang Zhao
- State Key Laboratory of Macromolecular Drugs and Large-Scale Manufacturing, School of Pharmaceutical Sciences, Liaocheng University, Liaocheng 252059, China
- NMPA Key Laboratory for Quality Control of Therapeutic Monoclonal Antibodies, Shanghai 201203, China
| | - Fugui Wang
- State Key Laboratory of Macromolecular Drugs and Large-Scale Manufacturing, School of Pharmaceutical Sciences, Liaocheng University, Liaocheng 252059, China
- NMPA Key Laboratory for Quality Control of Therapeutic Monoclonal Antibodies, Shanghai 201203, China
| | - Yanni Mao
- Waters Corporation, Shanghai 200126, China
| | | | | | - Lusha Ji
- State Key Laboratory of Macromolecular Drugs and Large-Scale Manufacturing, School of Pharmaceutical Sciences, Liaocheng University, Liaocheng 252059, China
- NMPA Key Laboratory for Quality Control of Therapeutic Monoclonal Antibodies, Shanghai 201203, China
- State Key Laboratory of Macromolecular Drugs and Large-Scale Manufacturing, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, China
| | - Weizhu Qian
- State Key Laboratory of Macromolecular Drugs and Large-Scale Manufacturing, School of Pharmaceutical Sciences, Liaocheng University, Liaocheng 252059, China
- NMPA Key Laboratory for Quality Control of Therapeutic Monoclonal Antibodies, Shanghai 201203, China
- State Key Laboratory of Macromolecular Drugs and Large-Scale Manufacturing, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, China
| | - Sheng Hou
- State Key Laboratory of Macromolecular Drugs and Large-Scale Manufacturing, School of Pharmaceutical Sciences, Liaocheng University, Liaocheng 252059, China
- NMPA Key Laboratory for Quality Control of Therapeutic Monoclonal Antibodies, Shanghai 201203, China
- State Key Laboratory of Macromolecular Drugs and Large-Scale Manufacturing, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, China
| | - Rui Wang
- State Key Laboratory of Macromolecular Drugs and Large-Scale Manufacturing, School of Pharmaceutical Sciences, Liaocheng University, Liaocheng 252059, China
| | - Jun Li
- State Key Laboratory of Macromolecular Drugs and Large-Scale Manufacturing, School of Pharmaceutical Sciences, Liaocheng University, Liaocheng 252059, China
- NMPA Key Laboratory for Quality Control of Therapeutic Monoclonal Antibodies, Shanghai 201203, China
- State Key Laboratory of Macromolecular Drugs and Large-Scale Manufacturing, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, China
| | - Dapeng Zhang
- State Key Laboratory of Macromolecular Drugs and Large-Scale Manufacturing, School of Pharmaceutical Sciences, Liaocheng University, Liaocheng 252059, China
- NMPA Key Laboratory for Quality Control of Therapeutic Monoclonal Antibodies, Shanghai 201203, China
- State Key Laboratory of Macromolecular Drugs and Large-Scale Manufacturing, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, China
| | - Huaizu Guo
- State Key Laboratory of Macromolecular Drugs and Large-Scale Manufacturing, School of Pharmaceutical Sciences, Liaocheng University, Liaocheng 252059, China
- NMPA Key Laboratory for Quality Control of Therapeutic Monoclonal Antibodies, Shanghai 201203, China
- State Key Laboratory of Macromolecular Drugs and Large-Scale Manufacturing, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, China
- State Key Laboratory of Macromolecular Drugs and Large-Scale Manufacturing, Shanghai Zhangjiang Biotechnology Co., Ltd., Shanghai 201203, China
| |
Collapse
|
3
|
Buckley C, Millán-Martín S, Carillo S, Füssl F, MacHale C, Bones J. Implementation of a LC-MS based multi-attribute method (MAM) and intact multi-attribute method (iMAM) workflow for the characterisation of a GLP-Fc fusion protein. Anal Biochem 2024; 693:115585. [PMID: 38851475 DOI: 10.1016/j.ab.2024.115585] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2024] [Revised: 05/17/2024] [Accepted: 06/05/2024] [Indexed: 06/10/2024]
Abstract
Over the past few years, the implementation of mass spectrometry (MS) in QC laboratories has become a more common occurrence. The multi-attribute method (MAM), and emerging intact multi-attribute method (iMAM), are powerful analytical tools utilising liquid chromatography-mass spectrometry (LC-MS) methods that enable the monitoring of critical quality attributes (CQAs) in biotherapeutic proteins in compliant settings. Both MAM and iMAM are intended to replace or supplement several conventional assays with a single LC-MS method utilising MS data in combination with robust, semi-automated data processing workflows. MAM and iMAM workflows can also be implemented into current Good Manufacturing Practices environments due to the availability of CFR 11 compliant chromatography data system software. In this study, MAM and iMAM are employed for the analysis of 4 batches of a glucagon-like peptide-Fc fusion protein. MAM approach involved a first the discovery phase for the identification of CQAs and second, the target monitoring phase of the selected CQAs in other samples. New peak detection was performed on the data set to determine the appearance, absence or change of any peak. For native iMAM workflow both size exclusion and strong cation exchange chromatography were optimized for the identification and monitoring of CQAs at the intact level.
Collapse
Affiliation(s)
- Ciarán Buckley
- Eli Lilly Kinsale Limited, Dunderrow, Kinsale, Co. Cork, P17 NY71, Ireland; School of Chemical and Bioprocess Engineering, University College Dublin, Belfield, Dublin, 4, D04 V1W8, Ireland
| | - Silvia Millán-Martín
- National Institute for Bioprocessing Research & Training, Fosters Avenue, Mount Merrion, Blackrock, A94 X099, Co. Dublin, Ireland
| | - Sara Carillo
- National Institute for Bioprocessing Research & Training, Fosters Avenue, Mount Merrion, Blackrock, A94 X099, Co. Dublin, Ireland
| | - Florian Füssl
- National Institute for Bioprocessing Research & Training, Fosters Avenue, Mount Merrion, Blackrock, A94 X099, Co. Dublin, Ireland
| | - Ciara MacHale
- Eli Lilly Kinsale Limited, Dunderrow, Kinsale, Co. Cork, P17 NY71, Ireland
| | - Jonathan Bones
- School of Chemical and Bioprocess Engineering, University College Dublin, Belfield, Dublin, 4, D04 V1W8, Ireland; National Institute for Bioprocessing Research & Training, Fosters Avenue, Mount Merrion, Blackrock, A94 X099, Co. Dublin, Ireland.
| |
Collapse
|
4
|
Khalikova M, Jireš J, Horáček O, Douša M, Kučera R, Nováková L. What is the role of current mass spectrometry in pharmaceutical analysis? MASS SPECTROMETRY REVIEWS 2024; 43:560-609. [PMID: 37503656 DOI: 10.1002/mas.21858] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/29/2022] [Revised: 06/02/2023] [Accepted: 06/25/2023] [Indexed: 07/29/2023]
Abstract
The role of mass spectrometry (MS) has become more important in most application domains in recent years. Pharmaceutical analysis is specific due to its stringent regulation procedures, the need for good laboratory/manufacturing practices, and a large number of routine quality control analyses to be carried out. The role of MS is, therefore, very different throughout the whole drug development cycle. While it dominates within the drug discovery and development phase, in routine quality control, the role of MS is minor and indispensable only for selected applications. Moreover, its role is very different in the case of analysis of small molecule pharmaceuticals and biopharmaceuticals. Our review explains the role of current MS in the analysis of both small-molecule chemical drugs and biopharmaceuticals. Important features of MS-based technologies being implemented, method requirements, and related challenges are discussed. The differences in analytical procedures for small molecule pharmaceuticals and biopharmaceuticals are pointed out. While a single method or a small set of methods is usually sufficient for quality control in the case of small molecule pharmaceuticals and MS is often not indispensable, a large panel of methods including extensive use of MS must be used for quality control of biopharmaceuticals. Finally, expected development and future trends are outlined.
Collapse
Affiliation(s)
- Maria Khalikova
- Department of Analytical Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University, Hradec Králové, Czech Republic
- Department of Chemistry, Faculty of Science, University of Hradec Králové, Hradec Králové, Czech Republic
| | - Jakub Jireš
- Department of Analytical Chemistry, Faculty of Chemical Engineering, UCT Prague, Prague, Czech Republic
- Department of Development, Zentiva, k. s., Praha, Praha, Czech Republic
| | - Ondřej Horáček
- Department of Pharmaceutical Chemistry and Pharmaceutical Analysis, Faculty of Pharmacy in Hradec Králové, Charles University, Hradec Králové, Czech Republic
| | - Michal Douša
- Department of Development, Zentiva, k. s., Praha, Praha, Czech Republic
| | - Radim Kučera
- Department of Pharmaceutical Chemistry and Pharmaceutical Analysis, Faculty of Pharmacy in Hradec Králové, Charles University, Hradec Králové, Czech Republic
| | - Lucie Nováková
- Department of Analytical Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University, Hradec Králové, Czech Republic
| |
Collapse
|
5
|
Shipman J, Karfunkle M, Zhu H, Zhuo Y, Chen K, Patabandige M, Wu D, Oyugi M, Kerr R, Yang K, Rogstad S. Assessment of monoclonal antibody glycosylation: a comparative study using HRMS, NMR, and HILIC-FLD. Anal Bioanal Chem 2024; 416:3127-3137. [PMID: 38580890 DOI: 10.1007/s00216-024-05261-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2023] [Revised: 03/10/2024] [Accepted: 03/12/2024] [Indexed: 04/07/2024]
Abstract
Monoclonal antibodies (mAbs) represent the largest class of therapeutic protein drug products. mAb glycosylation produces a heterogeneous, analytically challenging distribution of glycoforms that typically should be adequately characterized because glycosylation-based product quality attributes (PQAs) can impact product quality, immunogenicity, and efficacy. In this study, two products were compared using a panel of analytical methods. Two high-resolution mass spectrometry (HRMS) workflows were used to analyze N-glycans, while nuclear magnetic resonance (NMR) was used to generate monosaccharide fingerprints. These state-of-the-art techniques were compared to conventional analysis using hydrophilic interaction chromatography (HILIC) coupled with fluorescence detection (FLD). The advantages and disadvantages of each method are discussed along with a comparison of the identified glycan distributions. The results demonstrated agreement across all methods for major glycoforms, demonstrating how confidence in glycan characterization is increased by combining orthogonal analytical methodologies. The full panel of methods used represents a diverse toolbox that can be selected from based on the needs for a specific product or analysis.
Collapse
Affiliation(s)
- Joshua Shipman
- Division of Complex Drug Analysis, Office of Testing and Research, Center for Drug Evaluation and Research, US Food and Drug Administration, St Louis, MO, 63110, USA
| | - Michael Karfunkle
- Division of Pharmaceutical Analysis, Office of Testing and Research, Center for Drug Evaluation and Research, US Food and Drug Administration, St Louis, MO, 63110, USA
| | - Hongbin Zhu
- Division of Complex Drug Analysis, Office of Testing and Research, Center for Drug Evaluation and Research, US Food and Drug Administration, St Louis, MO, 63110, USA
| | - You Zhuo
- Division of Complex Drug Analysis, Office of Testing and Research, Center for Drug Evaluation and Research, US Food and Drug Administration, St Louis, MO, 63110, USA
- Office of Biotechnology Products, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, 20903, USA
| | - Kang Chen
- Division of Complex Drug Analysis, Office of Testing and Research, Center for Drug Evaluation and Research, US Food and Drug Administration, St Louis, MO, 63110, USA
| | - Milani Patabandige
- Division of Complex Drug Analysis, Office of Testing and Research, Center for Drug Evaluation and Research, US Food and Drug Administration, St Louis, MO, 63110, USA
- Center for Devices and Radiological Health, US Food and Drug Administration, Silver Spring, MD, 20903, USA
| | - Di Wu
- Immediate Office, Office of Testing and Research, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, 20993, USA
- AbbVie, South San Francisco, San Francisco, CA, 94080, USA
| | - Mercy Oyugi
- Immediate Office, Office of Testing and Research, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, 20993, USA
- Office of Biotechnology Products, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, 20903, USA
| | - Richard Kerr
- Division of Pharmaceutical Analysis, Office of Testing and Research, Center for Drug Evaluation and Research, US Food and Drug Administration, St Louis, MO, 63110, USA
- Sanofi, Framingham, MA, 01701, USA
| | - Kui Yang
- Division of Complex Drug Analysis, Office of Testing and Research, Center for Drug Evaluation and Research, US Food and Drug Administration, St Louis, MO, 63110, USA
| | - Sarah Rogstad
- Immediate Office, Office of Testing and Research, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, 20993, USA.
| |
Collapse
|
6
|
Dawdy AW, Trujillo EA, Liu Z, Crone C, Kraegenbring J, Scheffler K. Improved Mass Accuracy and Precision for Multi-Attribute Methods Using a New Internally Calibrated High Resolution Orbitrap Mass Detector. Anal Chem 2024; 96:6528-6533. [PMID: 38626116 DOI: 10.1021/acs.analchem.4c00520] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/18/2024]
Abstract
In the development of biotherapeutics, a thorough understanding of a molecule's product quality attributes (PQAs) and their effect on structure-function relationships and long-term stability is essential for ensuring the safety and efficacy of the product. First published in 2015, the multi-attribute method (MAM), based on LC-MS peptide mapping and automation principles, can be used to support biotherapeutic process and product development. The MAM provides simultaneous site-specific detection, identification, quantitation, and quality control monitoring of selected PQAs. In this article, a low-maintenance MAM-ready mass detector with a small footprint was evaluated for its ability to monitor PQAs on proteolytically digested proteins with high mass accuracy and precision. Optimized source parameters enable robust relative quantitation of attributes with high sensitivity and minimal in-source fragmentation. A combination of a built-in one-point mass calibration procedure prior to data acquisition and Scan-to-Scan on-the-fly mass correction allows monitoring of most peptides for at least 54 days with sub-1 ppm mass accuracies at high-resolution (180,000 at m/z 200). This enables the use of <3 ppm mass tolerances for peptide monitoring, supporting high method specificity and robustness. LC-MS based MAM data from this instrument compares well to data collected by earlier MAM systems and conventional HPLC profile-based drug substance release assays.
Collapse
Affiliation(s)
- Andrew W Dawdy
- BioTherapeutics Pharmaceutical Sciences, Pfizer Inc., Chesterfield, Missouri 63017, United States
| | - Edna A Trujillo
- BioTherapeutics Pharmaceutical Sciences, Pfizer Inc., Chesterfield, Missouri 63017, United States
| | - Zhenjiu Liu
- BioTherapeutics Pharmaceutical Sciences, Pfizer Inc., Chesterfield, Missouri 63017, United States
| | | | | | | |
Collapse
|
7
|
Schachner LF, Mullen C, Phung W, Hinkle JD, Beardsley MI, Bentley T, Day P, Tsai C, Sukumaran S, Baginski T, DiCara D, Agard NJ, Masureel M, Gober J, ElSohly AM, Melani R, Syka JEP, Huguet R, Marty MT, Sandoval W. Exposing the molecular heterogeneity of glycosylated biotherapeutics. Nat Commun 2024; 15:3259. [PMID: 38627419 PMCID: PMC11021452 DOI: 10.1038/s41467-024-47693-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2023] [Accepted: 04/10/2024] [Indexed: 04/19/2024] Open
Abstract
The heterogeneity inherent in today's biotherapeutics, especially as a result of heavy glycosylation, can affect a molecule's safety and efficacy. Characterizing this heterogeneity is crucial for drug development and quality assessment, but existing methods are limited in their ability to analyze intact glycoproteins or other heterogeneous biotherapeutics. Here, we present an approach to the molecular assessment of biotherapeutics that uses proton-transfer charge-reduction with gas-phase fractionation to analyze intact heterogeneous and/or glycosylated proteins by mass spectrometry. The method provides a detailed landscape of the intact molecular weights present in biotherapeutic protein preparations in a single experiment. For glycoproteins in particular, the method may offer insights into glycan composition when coupled with a suitable bioinformatic strategy. We tested the approach on various biotherapeutic molecules, including Fc-fusion, VHH-fusion, and peptide-bound MHC class II complexes to demonstrate efficacy in measuring the proteoform-level diversity of biotherapeutics. Notably, we inferred the glycoform distribution for hundreds of molecular weights for the eight-times glycosylated fusion drug IL22-Fc, enabling correlations between glycoform sub-populations and the drug's pharmacological properties. Our method is broadly applicable and provides a powerful tool to assess the molecular heterogeneity of emerging biotherapeutics.
Collapse
Affiliation(s)
- Luis F Schachner
- Department of Microchemistry, Proteomics and Lipidomics, Genentech, Inc., South San Francisco, CA, USA
| | - Christopher Mullen
- Life Sciences Mass Spectrometry, Thermo Fisher Scientific, Inc., San Jose, CA, USA
| | - Wilson Phung
- Department of Microchemistry, Proteomics and Lipidomics, Genentech, Inc., South San Francisco, CA, USA
| | - Joshua D Hinkle
- Life Sciences Mass Spectrometry, Thermo Fisher Scientific, Inc., San Jose, CA, USA
| | | | - Tracy Bentley
- Pharmaceutical Technical Development, Genentech, Inc., South San Francisco, CA, USA
| | - Peter Day
- Pharmaceutical Technical Development, Genentech, Inc., South San Francisco, CA, USA
| | - Christina Tsai
- Pharmaceutical Technical Development, Genentech, Inc., South San Francisco, CA, USA
- Protein Analytical Development, Ascendis Pharma, Palo Alto, CA, USA
| | - Siddharth Sukumaran
- Pharmaceutical Technical Development, Genentech, Inc., South San Francisco, CA, USA
- Translational Pharmacometrics, Janssen, Horsham, PA, USA
| | - Tomasz Baginski
- Pharmaceutical Technical Development, Genentech, Inc., South San Francisco, CA, USA
| | - Danielle DiCara
- Department of Antibody Engineering, Genentech, Inc., South San Francisco, CA, USA
| | - Nicholas J Agard
- Department of Antibody Engineering, Genentech, Inc., South San Francisco, CA, USA
| | - Matthieu Masureel
- Department of Structural Biology, Genentech, Inc., South San Francisco, CA, USA
| | - Joshua Gober
- Department of Protein Chemistry, Genentech, Inc., South San Francisco, CA, USA
| | - Adel M ElSohly
- Department of Protein Chemistry, Genentech, Inc., South San Francisco, CA, USA
| | - Rafael Melani
- Life Sciences Mass Spectrometry, Thermo Fisher Scientific, Inc., San Jose, CA, USA
| | - John E P Syka
- Life Sciences Mass Spectrometry, Thermo Fisher Scientific, Inc., San Jose, CA, USA
| | - Romain Huguet
- Life Sciences Mass Spectrometry, Thermo Fisher Scientific, Inc., San Jose, CA, USA
| | - Michael T Marty
- Department of Chemistry and Biochemistry, University of Arizona, Tucson, AZ, USA
| | - Wendy Sandoval
- Department of Microchemistry, Proteomics and Lipidomics, Genentech, Inc., South San Francisco, CA, USA.
| |
Collapse
|
8
|
Evans AR, Mulholland J, Lewis MJ, Hu P. Targeted CQA analytical control strategy for commercial antibody products: Replacing ion-exchange chromatography methods for charge heterogeneity with multi-attribute monitoring. MAbs 2024; 16:2341641. [PMID: 38652517 DOI: 10.1080/19420862.2024.2341641] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2024] [Accepted: 04/08/2024] [Indexed: 04/25/2024] Open
Abstract
Peptide mapping with mass spectrometry (MS) is an important tool for protein characterization in the biopharmaceutical industry. Historically, peptide mapping monitors post-translational modifications (PTMs) of protein products and process intermediates during development. Multi-attribute monitoring (MAM) methods have been used previously in commercial release and stability testing panels to ensure control of selected critical quality attributes (CQAs). Our goal is to use MAM methods as part of an overall analytical testing strategy specifically focused on CQAs, while removing or replacing historical separation methods that do not effectively distinguish CQAs from non-CQAs due to co-elution. For example, in this study, we developed a strategy to replace a profile-based ion-exchange chromatography (IEC) method using a MAM method in combination with traditional purity methods to ensure control of charge variant CQAs for a commercial antibody (mAb) drug product (DP). To support this change in commercial testing strategy, the charge variant CQAs were identified and characterized during development by high-resolution LC-MS and LC-MS/MS. The charge variant CQAs included PTMs, high molecular weight species, and low molecular weight species. Thus, removal of the IEC method from the DP specification was achieved using a validated LC-MS MAM method on a QDa system to directly measure the charge variant PTM CQAs in combination with size exclusion chromatography (SE-HPLC) and capillary electrophoresis (CE-SDS) to measure the non-PTM charge variant CQAs. Bridging data between the MAM, IEC, and SE-HPLC methods were included in the commercial marketing application to justify removing IEC from the DP specification. We have also used this MAM method as a test for identity to reduce the number of QC assays. This strategy has received approvals from several health authorities.
Collapse
Affiliation(s)
- Adam R Evans
- Therapeutics Development & Supply - Analytical Development, Janssen Pharmaceuticals Research and Development, Malvern, PA, USA
| | - Joseph Mulholland
- Therapeutics Development & Supply - Analytical Development, Janssen Pharmaceuticals Research and Development, Malvern, PA, USA
| | - Michael J Lewis
- Therapeutics Development & Supply - Analytical Development, Janssen Pharmaceuticals Research and Development, Malvern, PA, USA
| | - Ping Hu
- Therapeutics Development & Supply - Analytical Development, Janssen Pharmaceuticals Research and Development, Malvern, PA, USA
| |
Collapse
|
9
|
Mans J, Oyugi M, Asmelash B, Sommers C, Rogstad S. The Use of Mass Spectrometry in Therapeutic Protein Biologics License Applications: A Retrospective Review Revisited. JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY 2023; 34:2575-2584. [PMID: 37843827 DOI: 10.1021/jasms.3c00286] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/17/2023]
Abstract
Biologic license applications (BLAs) for 93 therapeutic proteins approved between 2016 and 2020 were analyzed for use of mass spectrometry (MS) as a follow up to a previous study that assessed MS use in BLAs from 2000 to 2015. Thirty percent of these BLAs were biosimilars, while only one biosimilar BLA was approved prior to 2016. This analysis evaluated the use of a variety of MS techniques and instrumentation. Results were further interpreted based on the relationship of MS use over time, between drug types, and between new drugs and biosimilars. MS data were included in 93 BLAs examined. The top eight quality attributes most assessed by MS in rank order were amino acid sequence, molecular mass, oxidation, disulfide bonds, deamidation, glycosylation, N-terminal sequence variants, and C-terminal sequence variants. These attributes were the same top attributes seen previously from BLAs approved between 2000 and 2015, and the use of MS to analyze them generally continued to increase across the new time frame. The average number of attributes analyzed by MS per BLA also continued to increase over the extended time frame of 21 years. High-resolution, accurate mass instrumentation such as the Orbitrap and time-of-flight (TOF) usage increased over time for all assessed attributes, while matrix-assisted laser desorption/ionization (MALDI)-TOF/(TOF) usage decreased. From highest to lowest rank, the top 11 attributes were antibody drug conjugate (ADC) characterization (i.e., drug load distribution/drug to antibody ratio (DAR), ADC and linkage site, and synthetic linker), isomerization, folding/higher-order structure (HOS), truncation, host cell proteins (HCPs), sequence variants (amino acid substitutions), succinimidation, glycation, PEGylation, charge variants, and oxidation.
Collapse
Affiliation(s)
- Jamie Mans
- Division of Complex Drug Analysis, Office of Testing and Research, Center for Drug Evaluation and Research, US Food and Drug Administration, St Louis, Missouri 63110, United States
| | - Mercy Oyugi
- Immediate Office, Office of Testing and Research, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland 20993, United States
| | - Bethel Asmelash
- Division of Complex Drug Analysis, Office of Testing and Research, Center for Drug Evaluation and Research, US Food and Drug Administration, St Louis, Missouri 63110, United States
| | - Cynthia Sommers
- Division of Complex Drug Analysis, Office of Testing and Research, Center for Drug Evaluation and Research, US Food and Drug Administration, St Louis, Missouri 63110, United States
| | - Sarah Rogstad
- Immediate Office, Office of Testing and Research, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland 20993, United States
| |
Collapse
|
10
|
Kristensen DB, Ørgaard M, Sloth TM, Comamala G, Jensen PF. Addressing Acid-Catalyzed Deamidation and the Solubility of Hydrophobic Peptides in Multi-Attribute Method Workflows. Anal Chem 2023; 95:15465-15471. [PMID: 37824441 PMCID: PMC10603607 DOI: 10.1021/acs.analchem.3c02609] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2023] [Accepted: 09/25/2023] [Indexed: 10/14/2023]
Abstract
Recently, we introduced an optimized and automated Multi-Attribute Method (MAM) workflow, which (a) significantly reduces the number of missed cleavages using an automated two-step digestion procedure and (b) dramatically reduces chromatographic peak tailing and carryover of hydrophobic peptides by implementing less retentive reversed-phase column chemistries. Here, further insights are provided on the impact of postdigest acidification and the importance of maintaining hydrophobic peptides in solution using strong chaotropic agents after digestion. We demonstrate how oxidation can significantly increase the solubility of hydrophobic peptides, a fact that can have a profound impact on quantitation of oxidation levels if care is not taken in MAM workflows. We conclude that (a) postdigestion acidification can result in significant acid-catalyzed deamidation during storage in an autosampler at 5 °C and (b) a strong chaotropic agent, such as guanidine hydrochloride, is critical for preventing loss of hydrophobic peptides through adsorption, which can result in (sometimes extreme) biases in quantitation of tryptophan oxidation levels. An optimized method is presented, which effectively addressed acid-catalyzed deamidation and solubility of hydrophobic peptides in MAM workflows.
Collapse
|
11
|
Rohskopf Z, Kwon T, Ko SH, Bozinovski D, Jeon H, Mohan N, Springs SL, Han J. Continuous Online Titer Monitoring in CHO Cell Culture Supernatant Using a Herringbone Nanofluidic Filter Array. Anal Chem 2023; 95:14608-14615. [PMID: 37733929 DOI: 10.1021/acs.analchem.3c02104] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/23/2023]
Abstract
Online monitoring of monoclonal antibody product titers throughout biologics process development and production enables rapid bioprocess decision-making and process optimization. Conventional analytical methods, including high-performance liquid chromatography and turbidimetry, typically require interfacing with an automated sampling system capable of online sampling and fractionation, which suffers from increased cost, a higher risk of failure, and a higher mechanical complexity of the system. In this study, a novel nanofluidic system for continuous direct (no sample preparation) IgG titer measurements was investigated. Tumor necrosis factor α (TNF-α), conjugated with fluorophores, was utilized as a selective binder for adalimumab in the unprocessed cell culture supernatant. The nanofluidic device can separate the bound complex from unbound TNF-α and selectively concentrate the bound complex for high-sensitivity detection. Based on the fluorescence intensity from the concentrated bound complex, a fluorescence intensity versus titer curve can be generated, which was used to determine the titer of samples from filtered, unpurified Chinese hamster ovary cell cultures continuously. The system performed direct monitoring of IgG titers with nanomolar resolution and showed a good correlation with the biolayer interferometry assays. Furthermore, by variation of the concentration of the indicator (TNF-α), the dynamic range of the system can be tuned and further expanded.
Collapse
Affiliation(s)
- Zhumei Rohskopf
- Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States
- Research Laboratory of Electronics, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States
| | - Taehong Kwon
- Research Laboratory of Electronics, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States
- Department of Electrical Engineering and Computer Science, Massachusetts Institute of Technology, Cambridge,Massachusetts 02139, United States
| | - Sung Hee Ko
- Research Laboratory of Electronics, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States
- Department of Electrical Engineering and Computer Science, Massachusetts Institute of Technology, Cambridge,Massachusetts 02139, United States
| | - Dragana Bozinovski
- Center for Biomedical Innovation, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States
| | - Hyungkook Jeon
- Research Laboratory of Electronics, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States
| | - Naresh Mohan
- Center for Biomedical Innovation, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States
| | - Stacy L Springs
- Center for Biomedical Innovation, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States
- Critical Analytics for Manufacturing Personalized-Medicine (CAMP) IRG, Singapore-MIT Alliance for Research and Technology (SMART) Centre, Singapore117583,Singapore
| | - Jongyoon Han
- Research Laboratory of Electronics, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States
- Department of Electrical Engineering and Computer Science, Massachusetts Institute of Technology, Cambridge,Massachusetts 02139, United States
- Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States
- Critical Analytics for Manufacturing Personalized-Medicine (CAMP) IRG, Singapore-MIT Alliance for Research and Technology (SMART) Centre, Singapore117583,Singapore
| |
Collapse
|
12
|
Gervais A, Dirksen EHC, Pohl T, Bechtold-Peters K, Burkitt W, D'Alessio V, Greven S, Lennard A, Li X, Lössner C, Niu B, Reusch D, O'Riordan T, Shearer JW, Spencer D, Xu W, Yi L. Compliance and regulatory considerations for the implementation of the multi-attribute-method by mass spectrometry in a quality control laboratory. Eur J Pharm Biopharm 2023; 191:57-67. [PMID: 37582411 DOI: 10.1016/j.ejpb.2023.08.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2023] [Revised: 08/04/2023] [Accepted: 08/12/2023] [Indexed: 08/17/2023]
Abstract
Multi-attribute methods employing mass spectrometry are applied throughout the biopharmaceutical industry for product and process characterization purposes but are not yet widely accepted as a method for batch release and stability testing under the good manufacturing practice (GMP) regime, due to limited experience and level of comfort with the technical, compliance and regulatory aspects of its implementation at quality control (QC) laboratories. This article is the second part of a two-tiered publication aiming at providing guidance for implementation of the multi-attribute method by peptide mapping liquid chromatography mass spectrometry (MAM) in a QC laboratory. The first part [1] focuses on technical considerations, while this second part provides considerations related to GMP compliance and regulatory aspects. This publication has been prepared by a group of industry experts representing 14 globally acting major biotechnology companies under the umbrella of the European Federation of Pharmaceutical Industries and Associations (EFPIA) Manufacturing & Quality Expert Group (MQEG).
Collapse
Affiliation(s)
- Annick Gervais
- Analytical Development Sciences for Biologicals, UCB, Chemin du Foriest, 1420 Braine L'Alleud, Belgium.
| | - Eef H C Dirksen
- Analytical Development and Quality Control, Byondis, Microweg 22, 6545 CM, Nijmegen, the Netherlands
| | - Thomas Pohl
- Biologics Analytical Development, Novartis Pharma AG, Klybeckstrasse 141, CH-4057 Basel, Switzerland
| | - Karoline Bechtold-Peters
- Biologics Drug Product Development, Novartis Pharma AG, Klybeckstrasse 141, CH-4057 Basel, Switzerland
| | - Will Burkitt
- Biological Characterisation Product Development Sciences, UCB, 216 Bath Road, Slough SL1 3WE, UK
| | - Valerio D'Alessio
- Analytical Development & Innovation NBE, Merck Serono S.p.A, Via Luigi Einaudi, 11, 00012 Guidonia Montecelio - Rome, Italy
| | - Simone Greven
- Pharmaceuticals, Biological Development, Bayer AG, Friedrich-Ebert-Strasse 217-333, 42117 Wuppertal, Germany
| | - Andrew Lennard
- Amgen Ltd, 4 Uxbridge Business Park, Sanderson Road, Uxbridge, UB8 1DH, UK
| | - Xue Li
- Biologics Development, Bristol Myers Squibb, 1 Squibb Drive, New Brunswick, NJ 08901, USA
| | - Christopher Lössner
- Analytical Dev. Biologicals, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Straße 65, 88397 Biberach an der Riß, Germany
| | - Ben Niu
- Biotherapeutics, Bristol Myers Squibb, 4224 Campus Point Court, San Diego, CA 92121, USA
| | - Dietmar Reusch
- Pharma Technical Development, Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg, Germany
| | - Tomás O'Riordan
- Eli Lilly Kinsale Limited, Dunderrow, Kinsale, Co. Cork, P17NY71, Ireland
| | - Justin W Shearer
- Analytical Development, GSK, 709 Swedeland Road, King of Prussia, PA 19406, USA
| | - David Spencer
- BioPharmaceutical Development, Ipsen Biopharm Limited, 9 Ash Road, Wrexham Industrial Estate, Wrexham LL13 9UF, UK
| | - Wei Xu
- Analytical Sciences, BioPharmaceuticals R&D, AstraZeneca, One Medimmune Way, Gaithersburg, MD 20878, USA
| | - Linda Yi
- Analytical Development, Biogen, 5000 Davis Drive, Research Triangle Park, NC 27709, USA
| |
Collapse
|
13
|
Oyugi M, Wang X, Yang X, Wu D, Rogstad S. Method validation and new peak detection for the liquid chromatography-mass spectrometry multi-attribute method. J Pharm Biomed Anal 2023; 234:115564. [PMID: 37451094 DOI: 10.1016/j.jpba.2023.115564] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2023] [Revised: 06/27/2023] [Accepted: 07/04/2023] [Indexed: 07/18/2023]
Abstract
The multi-attribute method (MAM) is a liquid chromatography-mass spectrometry (LC-MS) peptide mapping technique that has been proposed as a replacement for several conventional quality control (QC) methods for therapeutic proteins. In addition to quantification of multiple product quality attributes (PQAs), MAM can also monitor impurities using a new peak detection (NPD) feature. Here, results are provided from method validation and NPD studies of an MAM approach applied to rituximab as a model monoclonal antibody (mAb). Twenty-one rituximab PQAs were monitored, including oxidation, pyroglutamination, deamidation, lysine clipping, and glycosylation. The PQA monitoring aspect of the method was validated according to ICH Guidance. Accuracy, precision, specificity, detection and quantitation limits, linearity, range, and robustness were demonstrated for this MAM approach with minimal issues. All PQAs were successfully validated except for several oxidation sites, which did not pass intermediate precision criteria. The variability found in oxidation measurements was attributed to artificial oxidation during sample preparation and could likely be alleviated through several approaches. The NPD aspect of the method was also evaluated. A spike-in approach was used to assess the limits of detection and quantitation (LOD/LOQ) of the NPD feature of MAM. For NPD, the peak intensity threshold was found to be the most critical parameter for accurate detection of impurities since a low threshold can result in false positives while a high threshold can obscure the detection of true peaks. Overall, the MAM approach presented and validated here has been demonstrated to be suitable for both targeted monitoring of rituximab PQAs and non-targeted detection of new peaks that represent impurities.
Collapse
Affiliation(s)
- Mercy Oyugi
- Office of Biotechnology Products, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20903, USA; Office of Testing and Research, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20903, USA
| | - Xiaoshi Wang
- Office of Biotechnology Products, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20903, USA; Office of Testing and Research, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20903, USA
| | - Xiangkun Yang
- Office of Testing and Research, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20903, USA; Prime Medicine, Cambridge, MA 02139, USA
| | - Di Wu
- Office of Testing and Research, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20903, USA; AbbVie, South San Francisco, CA 94080, USA
| | - Sarah Rogstad
- Office of Testing and Research, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20903, USA.
| |
Collapse
|
14
|
Li X. Recent applications of quantitative mass spectrometry in biopharmaceutical process development and manufacturing. J Pharm Biomed Anal 2023; 234:115581. [PMID: 37494866 DOI: 10.1016/j.jpba.2023.115581] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2023] [Revised: 06/27/2023] [Accepted: 07/12/2023] [Indexed: 07/28/2023]
Abstract
Biopharmaceutical products have seen rapid growth over the past few decades and continue to dominate the global pharmaceutical market. Aligning with the quality by design (QbD) framework and realization, recent advances in liquid chromatography-mass spectrometry (LC-MS) instrumentation and related techniques have enhanced biopharmaceutical characterization capabilities and have supported an increased development of biopharmaceutical products. Beyond its routine qualitative characterization, the quantitative feature of LC-MS has unique applications in biopharmaceutical process development and manufacturing. This review describes the recent applications and implications of the advancement of quantitative MS methods in biopharmaceutical process development, and characterization of biopharmaceutical product, product-related variants, and process-related impurities. We also provide insights on the emerging applications of quantitative MS in the lifecycle of biopharmaceutical product development including quality control in the Good Manufacturing Practice (GMP) environment and process analytical technology (PAT) practices during process development and manufacturing. Through collaboration with instrument and software vendors and regulatory agencies, we envision broader adoption of phase-appropriate quantitative MS-based methods for the analysis of biopharmaceutical products, which in turn has the potential to enable manufacture of higher quality products for patients.
Collapse
Affiliation(s)
- Xuanwen Li
- Analytical Research and Development, MRL, Merck & Co., Inc., 126 E. Lincoln Avenue, Rahway, NJ 07065, USA.
| |
Collapse
|
15
|
Liu YD, Beardsley MI, Yang F. Expanding the Analytical Toolbox: Developing New Lys-C Peptide Mapping Methods with Minimized Assay-Induced Artifacts to Fully Characterize Antibodies. Pharmaceuticals (Basel) 2023; 16:1327. [PMID: 37765135 PMCID: PMC10536426 DOI: 10.3390/ph16091327] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2023] [Revised: 09/15/2023] [Accepted: 09/18/2023] [Indexed: 09/29/2023] Open
Abstract
Peptide mapping is an important tool used to confirm that the correct sequence has been expressed for a protein and to evaluate protein post-translational modifications (PTMs) that may arise during the production, processing, or storage of protein drugs. Our new orally administered drug (Ab-1), a single-domain antibody, is highly stable and resistant to proteolysis. Analysis via the commonly used tryptic mapping method did not generate sufficient sequence coverage. Alternative methods were needed to study the Ab-1 drug substance (75 mg/mL) and drug product (3 mg/mL). To meet these analytical needs, we developed two new peptide mapping methods using lysyl endopeptidase (Lys-C) digestion. These newly developed protein digestion protocols do not require desalting/buffer-exchange steps, thereby reducing sample preparation time and improving method robustness. Additionally, the protein digestion is performed under neutral pH with methionine acting as a scavenger to minimize artifacts, such as deamidation and oxidation, which are induced during sample preparation. Further, the method for low-concentration samples performs comparably to the method for high-concentration samples. Both methods provide 100% sequence coverage for Ab-1, and, therefore, enable comprehensive characterization for its product quality attribute (PQA) assessment. Both methods can be used to study other antibody formats.
Collapse
Affiliation(s)
| | | | - Feng Yang
- Department of Protein Analytical Chemistry, Genentech/Roche, South San Francisco, CA 94080, USA; (Y.D.L.); (M.I.B.)
| |
Collapse
|
16
|
Zhang Z, Richardson J, Shah B. Method for detecting rare differences between two LC-MS runs. Anal Biochem 2023:115211. [PMID: 37302778 DOI: 10.1016/j.ab.2023.115211] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2023] [Revised: 06/04/2023] [Accepted: 06/08/2023] [Indexed: 06/13/2023]
Abstract
LC-MS based multi-attribute methods (MAM) have drawn substantial attention due to their capability of simultaneously monitoring a large number of quality attributes of a biopharmaceutical product. For successful implementation of MAM, it is usually considered a requirement that the method is capable of detecting any new or missing peaks in the sample when compared to a control. Comparing a sample to a control for rare differences is also commonly practiced in many fields for investigational purpose. Because MS signal variability differs greatly between signals of different intensities, this type of comparison is often challenging, especially when the comparison is made without enough replicates. In this report we describe a statistical method for detecting rare differences between two very similar samples without replicate analyses. The method assumes that an overwhelming majority of components have equivalent abundance between the two samples, and signals with similar intensities have similar relative variability. By analyzing several monoclonal antibody peptide mapping datasets, we demonstrated that the method is suitable for new-peak detection for MAM as well as for other applications when rare differences between two samples need to be detected. The method greatly reduced false positive rate without a significant increase of false negative rate.
Collapse
Affiliation(s)
- Zhongqi Zhang
- Process Development, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA, 91320, USA.
| | - Jason Richardson
- Process Development, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA, 91320, USA
| | - Bhavana Shah
- Process Development, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA, 91320, USA
| |
Collapse
|
17
|
Akamine P, González-Feliciano JA, Almodóvar R, Morell G, Rivera J, Capó-Vélez CM, Delgado-Vélez M, Prieto-Costas L, Madera B, Eichinger D, Pino I, Rivera JH, Ortiz-Ubarri J, Rivera JM, Baerga-Ortiz A, Lasalde-Dominicci JA. Optimizing the Production of gp145, an HIV-1 Envelope Glycoprotein Vaccine Candidate and Its Encapsulation in Guanosine Microparticles. Vaccines (Basel) 2023; 11:975. [PMID: 37243079 PMCID: PMC10221277 DOI: 10.3390/vaccines11050975] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2023] [Revised: 04/14/2023] [Accepted: 05/04/2023] [Indexed: 05/28/2023] Open
Abstract
We have developed a pipeline to express, purify, and characterize HIV envelope protein (Env) gp145 from Chinese hamster ovary cells, to accelerate the production of a promising vaccine candidate. First in shake flasks, then in bioreactors, we optimized the growth conditions. By adjusting the pH to 6.8, we increased expression levels to 101 mg/L in a 50 L bioreactor, nearly twice the previously reported titer value. A battery of analytical methods was developed in accordance with current good manufacturing practices to ensure a quality biopharmaceutical. Imaged capillary isoelectric focusing verified proper glycosylation of gp145; dynamic light scattering confirmed the trimeric arrangement; and bio-layer interferometry and circular dichroism analysis demonstrated native-like properties (i.e., antibody binding and secondary structure). MALDI-TOF mass spectrometry was used as a multi-attribute platform for accurate mass determination, glycans analysis, and protein identification. Our robust analysis demonstrates that our gp145 product is very similar to a reference standard and emphasizes the importance of accurate characterization of a highly heterogeneous immunogen for the development of an effective vaccine. Finally, we present a novel guanosine microparticle with gp145 encapsulated and displayed on its surface. The unique properties of our gp145 microparticle make it amenable to use in future preclinical and clinical trials.
Collapse
Affiliation(s)
- Pearl Akamine
- Clinical Bioreagent Center, Molecular Sciences Research Center, University of Puerto Rico, San Juan 00926, Puerto Rico (M.D.-V.); (A.B.-O.)
| | - José A. González-Feliciano
- Clinical Bioreagent Center, Molecular Sciences Research Center, University of Puerto Rico, San Juan 00926, Puerto Rico (M.D.-V.); (A.B.-O.)
| | | | | | | | - Coral M. Capó-Vélez
- Clinical Bioreagent Center, Molecular Sciences Research Center, University of Puerto Rico, San Juan 00926, Puerto Rico (M.D.-V.); (A.B.-O.)
| | - Manuel Delgado-Vélez
- Clinical Bioreagent Center, Molecular Sciences Research Center, University of Puerto Rico, San Juan 00926, Puerto Rico (M.D.-V.); (A.B.-O.)
- Department of Biology, Río Piedras Campus, University of Puerto Rico, San Juan 00931, Puerto Rico
| | - Luis Prieto-Costas
- Department of Chemistry, Río Piedras Campus, University of Puerto Rico, San Juan 00925, Puerto Rico
| | - Bismark Madera
- Clinical Bioreagent Center, Molecular Sciences Research Center, University of Puerto Rico, San Juan 00926, Puerto Rico (M.D.-V.); (A.B.-O.)
- Department of Biology, Río Piedras Campus, University of Puerto Rico, San Juan 00931, Puerto Rico
| | | | | | | | - José Ortiz-Ubarri
- Department of Computer Sciences, Río Piedras Campus, University of Puerto Rico, San Juan 00925, Puerto Rico
| | - José M. Rivera
- Department of Chemistry, Río Piedras Campus, University of Puerto Rico, San Juan 00925, Puerto Rico
| | - Abel Baerga-Ortiz
- Clinical Bioreagent Center, Molecular Sciences Research Center, University of Puerto Rico, San Juan 00926, Puerto Rico (M.D.-V.); (A.B.-O.)
- Department of Biochemistry, Medical Sciences Campus, University of Puerto Rico, San Juan 00936, Puerto Rico
| | - José A. Lasalde-Dominicci
- Clinical Bioreagent Center, Molecular Sciences Research Center, University of Puerto Rico, San Juan 00926, Puerto Rico (M.D.-V.); (A.B.-O.)
- Department of Biology, Río Piedras Campus, University of Puerto Rico, San Juan 00931, Puerto Rico
- Department of Chemistry, Río Piedras Campus, University of Puerto Rico, San Juan 00925, Puerto Rico
- Institute of Neurobiology, Medical Sciences Campus, University of Puerto Rico, San Juan 00901, Puerto Rico
| |
Collapse
|
18
|
Pohl T, Gervais A, Dirksen E, D'Alessio V, Bechtold-Peters K, Burkitt W, Cao L, Greven S, Lennard A, Li X, Lössner C, Niu B, Reusch D, O'Riordan T, Shearer J, Spencer D, Xu W, Yi L. Technical considerations for the implementation of the Multi-Attribute-Method by mass spectrometry in a Quality Control laboratory. Eur J Pharm Biopharm 2023:S0939-6411(23)00112-1. [PMID: 37146738 DOI: 10.1016/j.ejpb.2023.04.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2023] [Revised: 04/27/2023] [Accepted: 04/28/2023] [Indexed: 05/07/2023]
Abstract
Multi-attribute methods employing mass spectrometry are applied throughout the biopharmaceutical industry for product and process characterization purposes but are not yet widely accepted as a method for batch release and stability testing under good manufacturing practice (GMP) due to limited experience and level of comfort with the technical, compliance and regulatory aspects of its implementation at quality control (QC) laboratories. Here, current literature related to the development and application of the multi-attribute method by peptide mapping liquid chromatography mass spectrometry (MAM) is compiled with the aim of providing guidance for the implementation of MAM in a QC laboratory. This article, focusing on technical considerations, is the first part of a two-tiered publication, whereby the second part will focus on GMP compliance and regulatory aspects. This publication has been prepared by a group of industry experts representing 14 globally acting major biotechnology companies under the umbrella of the European Federation of Pharmaceutical Industries and Associations (EFPIA) Manufacturing & Quality Expert Group (MQEG).
Collapse
Affiliation(s)
- Thomas Pohl
- Biologics Analytical Development, Novartis Pharma AG, Klybeckstrasse 141, CH-4057 Basel, Switzerland
| | - Annick Gervais
- Analytical Development Sciences for Biologicals, UCB, Chemin du Foriest, 1420 Braine L'Alleud, Belgium
| | - Eef Dirksen
- Analytical Development and Quality Control, Byondis, Microweg 22, 6545 CM, Nijmegen, The Netherlands
| | - Valerio D'Alessio
- Analytical Development Biotech, Merck Serono S.p.A., Via Luigi Einaudi, 11, 00012 Guidonia Montecelio - Rome, Italy
| | - Karoline Bechtold-Peters
- Biologics Drug Product Development, Novartis Pharma AG, Klybeckstrasse 141, CH-4057 Basel, Switzerland
| | - Will Burkitt
- Biological Characterisation Product Development Sciences, UCB, 216 Bath Road, Slough, SL1 3WE, UK
| | - Li Cao
- Strategic External Development, GSK, 1250 S. Collegeville Road, Collegeville, Pennsylvania 19426, USA
| | - Simone Greven
- Pharmaceuticals, Biological Development, Bayer AG, Friedrich-Ebert-Strasse 217-333, 42117 Wuppertal, Germany
| | - Andrew Lennard
- Amgen, 4 Uxbridge Business Park, Sanderson Road, Uxbridge, UB8 1DH, UK
| | - Xue Li
- Biologics Development, Bristol Myers Squibb, 1 Squibb Drive, New Brunswick, New Jersey 08901, USA
| | - Christopher Lössner
- Analytical Dev. Biologicals, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Straße 65, 88397 Biberach an der Riß, Germany
| | - Ben Niu
- Biotherapeutics, Bristol Myers Squibb, 4224 Campus Point Court, San Diego, California 92121, USA
| | - Dietmar Reusch
- Pharma Technical Development, Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg, Germany
| | - Tomás O'Riordan
- Eli Lilly Kinsale Limited, Dunderrow, Kinsale, Co. Cork, P17NY71, Ireland
| | - Justin Shearer
- Analytical Development, GSK, 709 Swedeland Road, King of Prussia, Pennsylvania 19406, USA
| | - David Spencer
- BioPharmaceutical Development, Ipsen Biopharm Limited, 9 Ash Road, Wrexham Industrial Estate, Wrexham, LL13 9UF, UK
| | - Wei Xu
- Analytical Sciences, BioPharmaceuticals R&D, AstraZeneca, One Medimmune Way, Gaithersburg, Maryland 20878, USA
| | - Linda Yi
- Analytical Development, Biogen, 5000 Davis Drive, Research Triangle Park, North Carolina 27709, USA
| |
Collapse
|
19
|
Cao W, Bruening ML. Analysis of Protein Glycosylation after Rapid Digestion Using Protease-Containing Membranes in Spin Columns. JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY 2023. [PMID: 37127550 DOI: 10.1021/jasms.3c00038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/03/2023]
Abstract
Glycosylation is an important protein post-translational modification that plays a pivotal role in the bioactivity of therapeutic proteins and in the infectivity of viral proteins. Liquid chromatography with tandem mass spectrometry readily identifies protein glycans with site specificity. However, the overnight incubation used in conventional in-solution proteolysis leads to high turnaround times for glycosylation analysis, particularly when sequential in-solution digestions are needed for site-specific glycan identification. Using bovine fetuin as a model glycoprotein, this work first shows that in-membrane digestion in ∼3 min yields similar glycan identification and quantitation when compared to overnight in-solution digestion. Protease-containing membranes in a spin column enable digestion of therapeutic proteins (trastuzumab and erythropoietin) and a viral protein (SARS-CoV-2 receptor binding domain) in ∼30 s. Glycan identification is similar after in-solution and in-membrane digestion, and limited in-membrane digestion enhances the identification of high-mannose glycans in trastuzumab. Finally, stacked membranes containing trypsin and chymotrypsin allow fast sequential proteolytic digestion to site-specifically identify the glycans of SARS-CoV-2 receptor binding domain. One can easily assemble the protease-containing membranes in commercial spin columns, and spinning multiple columns simultaneously will facilitate parallel analyses.
Collapse
Affiliation(s)
- Weikai Cao
- Department of Chemical and Biomolecular Engineering, University of Notre Dame, Notre Dame, Indiana 46556, United States
| | - Merlin L Bruening
- Department of Chemical and Biomolecular Engineering, University of Notre Dame, Notre Dame, Indiana 46556, United States
- Department of Chemistry, University of Notre Dame, Notre Dame, Indiana 46556, United States
| |
Collapse
|
20
|
Butré CI, D'Atri V, Diemer H, Colas O, Wagner E, Beck A, Cianferani S, Guillarme D, Delobel A. Interlaboratory Evaluation of a User-Friendly Benchtop Mass Spectrometer for Multiple-Attribute Monitoring Studies of a Monoclonal Antibody. Molecules 2023; 28:molecules28062855. [PMID: 36985827 PMCID: PMC10053224 DOI: 10.3390/molecules28062855] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2023] [Revised: 03/17/2023] [Accepted: 03/19/2023] [Indexed: 03/30/2023] Open
Abstract
In the quest to market increasingly safer and more potent biotherapeutic proteins, the concept of the multi-attribute method (MAM) has emerged from biopharmaceutical companies to boost the quality-by-design process development. MAM strategies rely on state-of-the-art analytical workflows based on liquid chromatography coupled to mass spectrometry (LC-MS) to identify and quantify a selected series of critical quality attributes (CQA) in a single assay. Here, we aimed at evaluating the repeatability and robustness of a benchtop LC-MS platform along with bioinformatics data treatment pipelines for peptide mapping-based MAM studies using standardized LC-MS methods, with the objective to benchmark MAM methods across laboratories, taking nivolumab as a case study. Our results evidence strong interlaboratory consistency across LC-MS platforms for all CQAs (i.e., deamidation, oxidation, lysine clipping and glycosylation). In addition, our work uniquely highlights the crucial role of bioinformatics postprocessing in MAM studies, especially for low-abundant species quantification. Altogether, we believe that MAM has fostered the development of routine, robust, easy-to-use LC-MS platforms for high-throughput determination of major CQAs in a regulated environment.
Collapse
Affiliation(s)
- Claire I Butré
- Quality Assistance sa, Technoparc de Thudinie 2, 6536 Thuin, Belgium
| | - Valentina D'Atri
- School of Pharmaceutical Sciences, University of Geneva, CMU-Rue Michel Servet 1, 1211 Geneva, Switzerland
- Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, CMU-Rue Michel Servet 1, 1211 Geneva, Switzerland
| | - Hélène Diemer
- Laboratoire de Spectrométrie de Masse BioOrganique, Université de Strasbourg, CNRS, IPHC UMR 7178, 67000 Strasbourg, France
- Infrastructure Nationale de Protéomique ProFI-FR2048, 67087 Strasbourg, France
| | - Olivier Colas
- Biologics CMC and Developability, IRPF, Centre d'Immunologie Pierre Fabre, 5 Avenue Napoleon III, 74160 Saint-Julien en Genevois, France
| | - Elsa Wagner
- Biologics CMC and Developability, IRPF, Centre d'Immunologie Pierre Fabre, 5 Avenue Napoleon III, 74160 Saint-Julien en Genevois, France
| | - Alain Beck
- Biologics CMC and Developability, IRPF, Centre d'Immunologie Pierre Fabre, 5 Avenue Napoleon III, 74160 Saint-Julien en Genevois, France
| | - Sarah Cianferani
- Laboratoire de Spectrométrie de Masse BioOrganique, Université de Strasbourg, CNRS, IPHC UMR 7178, 67000 Strasbourg, France
- Infrastructure Nationale de Protéomique ProFI-FR2048, 67087 Strasbourg, France
| | - Davy Guillarme
- School of Pharmaceutical Sciences, University of Geneva, CMU-Rue Michel Servet 1, 1211 Geneva, Switzerland
- Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, CMU-Rue Michel Servet 1, 1211 Geneva, Switzerland
| | - Arnaud Delobel
- Quality Assistance sa, Technoparc de Thudinie 2, 6536 Thuin, Belgium
| |
Collapse
|
21
|
Sadek M, Moore BN, Yu C, Ruppe N, Abdun-Nabi A, Hao Z, Alvarez M, Dahotre S, Deperalta G. A Robust Purity Method for Biotherapeutics Using New Peak Detection in an LC-MS-Based Multi-Attribute Method. JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY 2023; 34:484-492. [PMID: 36802331 DOI: 10.1021/jasms.2c00355] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/18/2023]
Abstract
New peak detection (NPD), as part of the LC-MS-based multi-attribute method (MAM), allows for sensitive and unbiased detection of new or changing site-specific attributes between a sample and reference that is not possible with conventional UV or fluorescence detection-based methods. MAM with NPD can serve as a purity test that can establish whether a sample and the reference are similar. The broad implementation of NPD in the biopharmaceutical industry has been limited by the potential presence of false positives or artifacts, which increase the analysis time and can trigger unnecessary investigations of product quality. Our novel contributions to the success of NPD are the curation of false positives, use of the known peak list concept, pairwise analysis approach, and the development of a NPD system suitability control strategy. In this report, we also introduce a unique experimental design utilizing sequence variant co-mixes to measure NPD performance. We show that NPD has superior performance relative to conventional control system methods in the detection of an unexpected change as compared with the reference. NPD is a new frontier in purity testing that reduces subjectivity, need for analyst intervention, and potential for missing unexpected product quality changes.
Collapse
Affiliation(s)
- Monica Sadek
- Protein Analytical Chemistry, Genentech, 1 DNA Way, South San Francisco, California 94080, United States
| | - Benjamin Nathan Moore
- Protein Analytical Chemistry, Genentech, 1 DNA Way, South San Francisco, California 94080, United States
| | - Christopher Yu
- Protein Analytical Chemistry, Genentech, 1 DNA Way, South San Francisco, California 94080, United States
| | - Nicholas Ruppe
- Protein Analytical Chemistry, Genentech, 1 DNA Way, South San Francisco, California 94080, United States
| | - Austin Abdun-Nabi
- Protein Analytical Chemistry, Genentech, 1 DNA Way, South San Francisco, California 94080, United States
| | - Zhiqi Hao
- Protein Analytical Chemistry, Genentech, 1 DNA Way, South San Francisco, California 94080, United States
| | - Melissa Alvarez
- Protein Analytical Chemistry, Genentech, 1 DNA Way, South San Francisco, California 94080, United States
| | - Sanket Dahotre
- Protein Analytical Chemistry, Genentech, 1 DNA Way, South San Francisco, California 94080, United States
| | - Galahad Deperalta
- Protein Analytical Chemistry, Genentech, 1 DNA Way, South San Francisco, California 94080, United States
| |
Collapse
|
22
|
Niu B, Lu Y, Chen X, Xu W. Using New Peak Detection to Solve Sequence Variants Analysis Challenges in Bioprocess Development. JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY 2023; 34:401-408. [PMID: 36705517 DOI: 10.1021/jasms.2c00292] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/18/2023]
Abstract
Recombinant therapeutic proteins have become the major class of drugs to treat various human diseases in recent years. Low levels of protein sequence variants (SVs) have been reported to be present in recombinant therapeutic proteins. The consequences of potential unwanted immune response from SVs of recombinant therapeutic proteins have increasingly drawn attention from regulatory authorities and the biopharmaceutical industry. It is highly desirable to detect low-level SVs during clone selection and early process development as part of the control strategy. Peptide mapping with LC-MS/MS analysis has been applied as a powerful tool to characterize post-translation modifications of therapeutic proteins. Despite the recent advancements in mass spectrometry hardware and software, it is still quite challenging and time-consuming to detect and identify low-level SVs. In this study, we present an optimized approach using new peak detection to detect and identify low level SVs with high confidence and high speed. The new approach makes sequence variants analysis by LC-MS/MS broadly applicable and practical in bioprocess development of therapeutic proteins.
Collapse
Affiliation(s)
- Ben Niu
- Analytical Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland20878United States
| | - Yali Lu
- Analytical Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland20878United States
| | - Xiaoyu Chen
- Analytical Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland20878United States
| | - Wei Xu
- Analytical Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland20878United States
| |
Collapse
|
23
|
Li X, Pierson NA, Hua X, Patel BA, Olma MH, Strulson CA, Letarte S, Richardson DD. Analytical Performance Evaluation of Identity, Quality-Attribute Monitoring and new Peak Detection in a Platform Multi-Attribute Method Using Lys-C Digestion for Characterization and Quality Control of Therapeutic Monoclonal Antibodies. J Pharm Sci 2023; 112:691-699. [PMID: 36279953 DOI: 10.1016/j.xphs.2022.10.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2022] [Revised: 10/15/2022] [Accepted: 10/15/2022] [Indexed: 11/06/2022]
Abstract
The use of multi-attribute method (MAM) for identity and purity testing of biopharmaceuticals offers the ability to complement and replace multiple conventional analytical technologies with a single mass spectrometry (MS) method. Phase-appropriate method validation is one major consideration for the implementation of MAM in a current Good Manufacturing Practice (cGMP) environment. We developed a MAM workflow for therapeutic monoclonal antibodies (mAbs) with optimized sample preparation using lysyl endopeptidase (Lys-C) digestion. In this study, we evaluated the assay performances of this platform MAM workflow for identity, product quality attributes (PQAs) monitoring and new peak detection (NPD) for single and coformulated mAbs. An IgG4 mAb-1 and its coformulations were used as model molecules in this study. The assay performance evaluation demonstrated the full potential of the platform MAM approach for its intended use for characterization and quality control of single mAb-1 and mAb-1 in its coformulations. To the best of our knowledge, this is the first performance evaluation of MAM for mAb identity, PQA monitoring, and new peak detection (NPD) in a single assay, featuring 1) the first performance evaluation of MAM for PQA monitoring using Lys-C digestion with a high-resolution MS, 2) a new approach for mAb identity testing capable of distinguishing single mAb from coformulations using MAM, and 3) the performance evaluation of NPD for MAM with Lys-C digestion. The developed platform MAM workflow and the MAM performance evaluation paved the way for its GMP qualification and enabled clinical release of mAb-1 in GMP environment with MAM.
Collapse
Affiliation(s)
- Xuanwen Li
- Analytical Research & Development, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, United States.
| | - Nicholas A Pierson
- Analytical Research & Development, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, United States
| | - Xiaoqing Hua
- Analytical Research & Development, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, United States
| | - Bhumit A Patel
- Analytical Research & Development, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, United States
| | - Michael H Olma
- Analytical Research & Development, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, United States
| | - Christopher A Strulson
- Analytical Research & Development, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, United States
| | - Simon Letarte
- Analytical Research & Development, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, United States
| | - Douglas D Richardson
- Analytical Research & Development, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, United States
| |
Collapse
|
24
|
Serrano MAC, Furman R, Chen G, Tao L. Mass spectrometry in gene therapy: Challenges and opportunities for AAV analysis. Drug Discov Today 2023; 28:103442. [PMID: 36396118 DOI: 10.1016/j.drudis.2022.103442] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2022] [Revised: 09/23/2022] [Accepted: 11/09/2022] [Indexed: 11/16/2022]
Abstract
The characterization of adeno-associated virus (AAV)-based gene therapy products represents significant challenges owing to their extremely large molecular sizes, structural complexity and heterogeneity, and limited sample amounts. Mass spectrometry (MS) is one of the key analytical tools that can overcome these challenges and serve as an important technique for the analysis of multiple attributes. In this review, the current methodologies and emerging trends in MS analysis of AAV gene therapy products are presented, highlighting their advantages and unique capabilities in addressing key issues encountered in intact AAV vector analysis, capsid viral protein characterization and impurity analysis.
Collapse
Affiliation(s)
- Mahalia A C Serrano
- Analytical Development and Attribute Sciences, Biologics Development, Global Product Development and Supply, Bristol Myers Squibb, New Brunswick, NJ, USA
| | - Ran Furman
- Analytical Development and Attribute Sciences, Biologics Development, Global Product Development and Supply, Bristol Myers Squibb, New Brunswick, NJ, USA
| | - Guodong Chen
- Analytical Development and Attribute Sciences, Biologics Development, Global Product Development and Supply, Bristol Myers Squibb, New Brunswick, NJ, USA.
| | - Li Tao
- Analytical Development and Attribute Sciences, Biologics Development, Global Product Development and Supply, Bristol Myers Squibb, New Brunswick, NJ, USA
| |
Collapse
|
25
|
Comprehensive multi-attribute method workflow for biotherapeutic characterization and current good manufacturing practices testing. Nat Protoc 2022; 18:1056-1089. [PMID: 36526726 DOI: 10.1038/s41596-022-00785-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2022] [Accepted: 10/04/2022] [Indexed: 12/23/2022]
Abstract
The multi-attribute method (MAM) is a liquid chromatography-mass spectrometry (LC-MS)-based method that is used to directly characterize and monitor numerous product quality attributes (PQAs) at the amino acid level of a biopharmaceutical product. MAM enables identity testing based on primary sequence verification, detection and quantitation of post-translational modifications and impurities. This ability to simultaneously and directly determine PQAs of therapeutic proteins makes MAM a more informative, streamlined and productive workflow than conventional chromatographic and electrophoretic assays. MAM relies on proteolytic digestion of the sample followed by reversed-phase chromatographic separation and high-resolution LC-MS analysis in two phases. First, a discovery study to determine quality attributes for monitoring is followed by the creation of a targeted library based on high-resolution retention time plus accurate mass analysis. The second aspect of MAM is the monitoring phase based on the target peptide library and new peak detection using differential analysis of the data to determine the presence, absence or change of any species that might affect the activity or stability of the biotherapeutic. The sample preparation process takes between 90 and 120 min, whereas the time spent on instrumental and data analyses might vary from one to several days for different sample sizes, depending on the complexity of the molecule, the number of attributes to be monitored and the information to be detailed in the final report. MAM is developed to be used throughout the product life cycle, from process development through upstream and downstream processes to quality control release or under current good manufacturing practices regulations enforced by regulatory agencies.
Collapse
|
26
|
Kristensen DB, Ørgaard M, Sloth TM, Christoffersen NS, Leth-Espensen KZ, Jensen PF. Optimized Multi-Attribute Method Workflow Addressing Missed Cleavages and Chromatographic Tailing/Carry-Over of Hydrophobic Peptides. Anal Chem 2022; 94:17195-17204. [PMID: 36346901 DOI: 10.1021/acs.analchem.2c03820] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Peptide mapping by liquid chromatography mass spectrometry (LC-MS) and the related multi-attribute method (MAM) are well-established analytical tools for verification of the primary structure and mapping/quantitation of co- and post-translational modifications (PTMs) or product quality attributes in biopharmaceutical development. Proteolytic digestion is a key step in peptide mapping workflows, which traditionally is labor-intensive, involving multiple manual steps. Recently, simple high-temperature workflows with automatic digestion were introduced, which facilitate robustness and reproducibility across laboratories. Here, a modified workflow with an automatic digestion step is presented, which includes a two-step digestion at high and low temperatures, as opposed to the original one-step digestion at a high temperature. The new automatic digestion workflow significantly reduces the number of missed cleavages, obtaining a more complete digestion profile. In addition, we describe how chromatographic peak tailing and carry-over is dramatically reduced for hydrophobic peptides by switching from the traditional C18 reversed-phase (RP) column chemistry used for peptide mapping to a less retentive C4 column chemistry. No negative impact is observed on MS/MS-derived sequence coverage when switching to a C4 column chemistry. Overall, the new peptide mapping workflow significantly reduces the number of missed cleavages, yielding more robust and simple data interpretation, while providing dramatically reduced tailing and carry-over of hydrophobic peptides.
Collapse
|
27
|
Instability Challenges and Stabilization Strategies of Pharmaceutical Proteins. Pharmaceutics 2022; 14:pharmaceutics14112533. [PMID: 36432723 PMCID: PMC9699111 DOI: 10.3390/pharmaceutics14112533] [Citation(s) in RCA: 13] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2022] [Revised: 11/13/2022] [Accepted: 11/17/2022] [Indexed: 11/22/2022] Open
Abstract
Maintaining the structure of protein and peptide drugs has become one of the most important goals of scientists in recent decades. Cold and thermal denaturation conditions, lyophilization and freeze drying, different pH conditions, concentrations, ionic strength, environmental agitation, the interaction between the surface of liquid and air as well as liquid and solid, and even the architectural structure of storage containers are among the factors that affect the stability of these therapeutic biomacromolecules. The use of genetic engineering, side-directed mutagenesis, fusion strategies, solvent engineering, the addition of various preservatives, surfactants, and additives are some of the solutions to overcome these problems. This article will discuss the types of stress that lead to instabilities of different proteins used in pharmaceutics including regulatory proteins, antibodies, and antibody-drug conjugates, and then all the methods for fighting these stresses will be reviewed. New and existing analytical methods that are used to detect the instabilities, mainly changes in their primary and higher order structures, are briefly summarized.
Collapse
|
28
|
Cook K, Kristensen DB, Ørgaard M, Sloth TM. Overcoming Incomplete Peptide Mapping of Antibody Complementarity-Determining Regions with Alternate Digestion Workflows. LCGC NORTH AMERICA 2022. [DOI: 10.56530/lcgc.na.pn1583m3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Peptide mapping of antibodies is an essential method to monitor peptide modifications in antibody lots that could affect the safety and efficacy of the product. Conventional protocols rely on protein digestion using proteases, such as trypsin, before mapping with mass spectrometry (MS). However, trypsin digestion may cause incomplete mapping of peptides, especially those that include highly hydrophobic peptides. Here, we show how pepsin can be used as an alternative and complementary protease for digestion that allows for improved sequence coverage, especially in proteins with highly hydrophobic regions. We also show that using guanidine hydrochloride (GuHCl) post-digestion improves peptide mapping results. Overall, these two methods—pepsin digestion and GuHCl post-digestion—can be used to provide more comprehensive antibody peptide maps, thereby enabling more thorough quality checking of biopharmaceutical products.
Collapse
|
29
|
Mouchahoir T, Schiel JE, Rogers R, Heckert A, Place BJ, Ammerman A, Li X, Robinson T, Schmidt B, Chumsae CM, Li X, Manuilov AV, Yan B, Staples GO, Ren D, Veach AJ, Wang D, Yared W, Sosic Z, Wang Y, Zang L, Leone AM, Liu P, Ludwig R, Tao L, Wu W, Cansizoglu A, Hanneman A, Adams GW, Perdivara I, Walker H, Wilson M, Brandenburg A, DeGraan-Weber N, Gotta S, Shambaugh J, Alvarez M, Yu XC, Cao L, Shao C, Mahan A, Nanda H, Nields K, Nightlinger N, Niu B, Wang J, Xu W, Leo G, Sepe N, Liu YH, Patel BA, Richardson D, Wang Y, Tizabi D, Borisov OV, Lu Y, Maynard EL, Gruhler A, Haselmann KF, Krogh TN, Sönksen CP, Letarte S, Shen S, Boggio K, Johnson K, Ni W, Patel H, Ripley D, Rouse JC, Zhang Y, Daniels C, Dawdy A, Friese O, Powers TW, Sperry JB, Woods J, Carlson E, Sen KI, Skilton SJ, Busch M, Lund A, Stapels M, Guo X, Heidelberger S, Kaluarachchi H, McCarthy S, Kim J, Zhen J, Zhou Y, Rogstad S, Wang X, Fang J, Chen W, Yu YQ, Hoogerheide JG, Scott R, Yuan H. Attribute Analytics Performance Metrics from the MAM Consortium Interlaboratory Study. JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY 2022; 33:1659-1677. [PMID: 36018776 PMCID: PMC9460773 DOI: 10.1021/jasms.2c00129] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/11/2022] [Revised: 08/01/2022] [Accepted: 08/02/2022] [Indexed: 05/23/2023]
Abstract
The multi-attribute method (MAM) was conceived as a single assay to potentially replace multiple single-attribute assays that have long been used in process development and quality control (QC) for protein therapeutics. MAM is rooted in traditional peptide mapping methods; it leverages mass spectrometry (MS) detection for confident identification and quantitation of many types of protein attributes that may be targeted for monitoring. While MAM has been widely explored across the industry, it has yet to gain a strong foothold within QC laboratories as a replacement method for established orthogonal platforms. Members of the MAM consortium recently undertook an interlaboratory study to evaluate the industry-wide status of MAM. Here we present the results of this study as they pertain to the targeted attribute analytics component of MAM, including investigation into the sources of variability between laboratories and comparison of MAM data to orthogonal methods. These results are made available with an eye toward aiding the community in further optimizing the method to enable its more frequent use in the QC environment.
Collapse
Affiliation(s)
- Trina Mouchahoir
- National
Institute of Standards and Technology, 100 Bureau Dr, Gaithersburg, Maryland 20899, United States
- Institute
for Bioscience and Biotechnology Research, 9600 Gudelsky Dr, Rockville, Maryland 20850, United States
| | - John E. Schiel
- National
Institute of Standards and Technology, 100 Bureau Dr, Gaithersburg, Maryland 20899, United States
- Institute
for Bioscience and Biotechnology Research, 9600 Gudelsky Dr, Rockville, Maryland 20850, United States
| | - Rich Rogers
- Just-Evotech
Biologics, Inc., 401
Terry Ave N., Seattle, Washington 98109, United States
| | - Alan Heckert
- National
Institute of Standards and Technology, 100 Bureau Dr, Gaithersburg, Maryland 20899, United States
| | - Benjamin J. Place
- National
Institute of Standards and Technology, 100 Bureau Dr, Gaithersburg, Maryland 20899, United States
| | - Aaron Ammerman
- AbbVie, 1000 Gateway
Blvd, South San Francisco, California 94080, United States
| | - Xiaoxiao Li
- AbbVie, 1000 Gateway
Blvd, South San Francisco, California 94080, United States
| | - Tom Robinson
- AbbVie, 1000 Gateway
Blvd, South San Francisco, California 94080, United States
| | - Brian Schmidt
- AbbVie, 1000 Gateway
Blvd, South San Francisco, California 94080, United States
| | - Chris M. Chumsae
- AbbVie, 100 Research Drive, Worcester, Massachusetts 01605, United States
| | - Xinbi Li
- AbbVie, 100 Research Drive, Worcester, Massachusetts 01605, United States
| | - Anton V. Manuilov
- AbbVie, 100 Research Drive, Worcester, Massachusetts 01605, United States
| | - Bo Yan
- AbbVie, 100 Research Drive, Worcester, Massachusetts 01605, United States
| | - Gregory O. Staples
- Agilent
Technologies, 5301 Stevens Creek Blvd, Santa Clara, California 95008, United States
| | - Da Ren
- Amgen, One Amgen Center Dr, Thousand
Oaks, California 91320, United States
| | - Alexander J. Veach
- Amgen, One Amgen Center Dr, Thousand
Oaks, California 91320, United States
| | - Dongdong Wang
- BioAnalytix, 790 Memorial Dr, Cambridge, Massachusetts 02139, United States
| | - Wael Yared
- BioAnalytix, 790 Memorial Dr, Cambridge, Massachusetts 02139, United States
| | - Zoran Sosic
- Biogen, 125 Broadway, Cambridge, Massachusetts 02142, United States
| | - Yan Wang
- Biogen, 125 Broadway, Cambridge, Massachusetts 02142, United States
| | - Li Zang
- Biogen, 125 Broadway, Cambridge, Massachusetts 02142, United States
| | - Anthony M. Leone
- Bristol-Myers
Squibb, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States
| | - Peiran Liu
- Bristol-Myers
Squibb, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States
| | - Richard Ludwig
- Bristol-Myers
Squibb, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States
| | - Li Tao
- Bristol-Myers
Squibb, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States
| | - Wei Wu
- Bristol-Myers
Squibb, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States
| | - Ahmet Cansizoglu
- Charles
River Laboratories, 8
Henshaw Street, Shrewsbury, Massachusetts 01801, United States
| | - Andrew Hanneman
- Charles
River Laboratories, 8
Henshaw Street, Shrewsbury, Massachusetts 01801, United States
| | - Greg W. Adams
- FUJIFILM
Diosynth Biotechnologies, 101 J. Morris Commons Ln, Morrisville, North Carolina 27560, United States
| | - Irina Perdivara
- FUJIFILM
Diosynth Biotechnologies, 101 J. Morris Commons Ln, Morrisville, North Carolina 27560, United States
| | - Hunter Walker
- FUJIFILM
Diosynth Biotechnologies, 101 J. Morris Commons Ln, Morrisville, North Carolina 27560, United States
| | - Margo Wilson
- FUJIFILM
Diosynth Biotechnologies, 101 J. Morris Commons Ln, Morrisville, North Carolina 27560, United States
| | | | - Nick DeGraan-Weber
- Genedata, 750 Marrett Road, One Cranberry
Hill, Lexington, Massachusetts 02421, United States
| | - Stefano Gotta
- Genedata, Margarethenstrasse 38, Basel, 4053, Switzerland
| | - Joe Shambaugh
- Genedata, 750 Marrett Road, One Cranberry
Hill, Lexington, Massachusetts 02421, United States
| | - Melissa Alvarez
- Genentech, 1 DNA Way, South San Francisco, California 94080, United States
| | - X. Christopher Yu
- Genentech, 1 DNA Way, South San Francisco, California 94080, United States
| | - Li Cao
- GSK, 709
Swedeland Rd, King of Prussia, Pennsylvania 19406, United States
| | - Chun Shao
- GSK, 709
Swedeland Rd, King of Prussia, Pennsylvania 19406, United States
| | - Andrew Mahan
- Janssen, 1400 McKean Road, Springhouse, Pennsylvania 19477, United States
| | - Hirsh Nanda
- Janssen, 1400 McKean Road, Springhouse, Pennsylvania 19477, United States
| | - Kristen Nields
- Janssen, 1400 McKean Road, Springhouse, Pennsylvania 19477, United States
| | - Nancy Nightlinger
- Just-Evotech
Biologics, Inc., 401
Terry Ave N., Seattle, Washington 98109, United States
| | - Ben Niu
- AstraZeneca, One MedImmune Way, Gaithersburg, Maryland 20878, United
States
| | - Jihong Wang
- AstraZeneca, One MedImmune Way, Gaithersburg, Maryland 20878, United
States
| | - Wei Xu
- AstraZeneca, One MedImmune Way, Gaithersburg, Maryland 20878, United
States
| | - Gabriella Leo
- EMD Serono an affiliate of Merck KGaA, Darmstadt, Germany, Via Luigi Einaudi 11, Guidonia Montecelio (Roma), 00012, Italy
| | - Nunzio Sepe
- EMD Serono an affiliate of Merck KGaA, Darmstadt, Germany, Via Luigi Einaudi 11, Guidonia Montecelio (Roma), 00012, Italy
| | - Yan-Hui Liu
- Merck
& Co., Inc.., 2000 Galloping Hill Rd, Kenilworth, New Jersey 07033, United States
| | - Bhumit A. Patel
- Merck
& Co., Inc.., 2000 Galloping Hill Rd, Kenilworth, New Jersey 07033, United States
| | - Douglas Richardson
- Merck
& Co., Inc.., 2000 Galloping Hill Rd, Kenilworth, New Jersey 07033, United States
| | - Yi Wang
- Merck
& Co., Inc.., 2000 Galloping Hill Rd, Kenilworth, New Jersey 07033, United States
| | - Daniela Tizabi
- National
Institute of Standards and Technology, 100 Bureau Dr, Gaithersburg, Maryland 20899, United States
- Institute
for Bioscience and Biotechnology Research, 9600 Gudelsky Dr, Rockville, Maryland 20850, United States
| | - Oleg V. Borisov
- Novavax,
Inc., 20 Firstfield Road, Gaithersburg, Maryland 20878, United States
| | - Yali Lu
- Novavax,
Inc., 20 Firstfield Road, Gaithersburg, Maryland 20878, United States
| | - Ernest L. Maynard
- Novavax,
Inc., 20 Firstfield Road, Gaithersburg, Maryland 20878, United States
| | | | | | | | | | - Simon Letarte
- Pfizer, 375 N Field Dr, Lake Forest, Illinois 60045, United
States
| | - Sean Shen
- Pfizer, 375 N Field Dr, Lake Forest, Illinois 60045, United
States
| | - Kristin Boggio
- Pfizer, 1 Burtt Rd, Andover, Massachusetts 01810, United States
| | - Keith Johnson
- Pfizer, 1 Burtt Rd, Andover, Massachusetts 01810, United States
| | - Wenqin Ni
- Pfizer, 1 Burtt Rd, Andover, Massachusetts 01810, United States
| | - Himakshi Patel
- Pfizer, 1 Burtt Rd, Andover, Massachusetts 01810, United States
| | - David Ripley
- Pfizer, 1 Burtt Rd, Andover, Massachusetts 01810, United States
| | - Jason C. Rouse
- Pfizer, 1 Burtt Rd, Andover, Massachusetts 01810, United States
| | - Ying Zhang
- Pfizer, 1 Burtt Rd, Andover, Massachusetts 01810, United States
| | - Carly Daniels
- Pfizer, 700 Chesterfield
Pkwy West, Chesterfield, Missouri 63017, United
States
| | - Andrew Dawdy
- Pfizer, 700 Chesterfield
Pkwy West, Chesterfield, Missouri 63017, United
States
| | - Olga Friese
- Pfizer, 700 Chesterfield
Pkwy West, Chesterfield, Missouri 63017, United
States
| | - Thomas W. Powers
- Pfizer, 700 Chesterfield
Pkwy West, Chesterfield, Missouri 63017, United
States
| | - Justin B. Sperry
- Pfizer, 700 Chesterfield
Pkwy West, Chesterfield, Missouri 63017, United
States
| | - Josh Woods
- Pfizer, 700 Chesterfield
Pkwy West, Chesterfield, Missouri 63017, United
States
| | - Eric Carlson
- Protein
Metrics, Inc., 20863
Stevens Creek Blvd, Cupertino, California 95014, United States
| | - K. Ilker Sen
- Protein
Metrics, Inc., 20863
Stevens Creek Blvd, Cupertino, California 95014, United States
| | - St John Skilton
- Protein
Metrics, Inc., 20863
Stevens Creek Blvd, Cupertino, California 95014, United States
| | - Michelle Busch
- Sanofi, 1 The Mountain Rd, Framingham, Massachusetts 01701, United States
| | - Anders Lund
- Sanofi, 1 The Mountain Rd, Framingham, Massachusetts 01701, United States
| | - Martha Stapels
- Sanofi, 1 The Mountain Rd, Framingham, Massachusetts 01701, United States
| | - Xu Guo
- SCIEX, 71 Four Valley Drive, Concord, ON L4K
4V8, Canada
| | | | | | - Sean McCarthy
- SCIEX, 500 Old Connecticut Path, Framingham, Massachusetts 01701, United States
| | - John Kim
- Teva, 145 Brandywine Pkwy, West Chester, Pennsylvania 19380, United States
| | - Jing Zhen
- Teva, 145 Brandywine Pkwy, West Chester, Pennsylvania 19380, United States
| | - Ying Zhou
- Teva, 145 Brandywine Pkwy, West Chester, Pennsylvania 19380, United States
| | - Sarah Rogstad
- U.S. Food
and Drug Administration, 10903 New Hampshire Ave, Silver Spring, Maryland 20993, United States
| | - Xiaoshi Wang
- U.S. Food
and Drug Administration, 10903 New Hampshire Ave, Silver Spring, Maryland 20993, United States
| | - Jing Fang
- Waters, 34 Maple St, Milford, Massachusetts 01757, United States
| | - Weibin Chen
- Waters, 34 Maple St, Milford, Massachusetts 01757, United States
| | - Ying Qing Yu
- Waters, 34 Maple St, Milford, Massachusetts 01757, United States
| | | | - Rebecca Scott
- Zoetis, 333 Portage St, Kalamazoo, Michigan 49007, United
States
| | - Hua Yuan
- Zoetis, 333 Portage St, Kalamazoo, Michigan 49007, United
States
| |
Collapse
|
30
|
Mass spectrometry-based multi-attribute method for mutation analysis in the early development of therapeutic proteins. J Pharm Biomed Anal 2022; 220:115018. [PMID: 36030755 DOI: 10.1016/j.jpba.2022.115018] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2022] [Revised: 08/15/2022] [Accepted: 08/19/2022] [Indexed: 11/22/2022]
Abstract
The early intervention is essential, and later development cannot compensate for this initial generation of an antibody drug. Especially for sequence variants (SVs), should cause concern during the early bioprocess development. The advancement of bioprocess development is paralleled by development of state-of-the-art analytical methods that will provide further information. In the present study, a mass spectrometry (MS)-based multi-attribute method (MAM) was used to simultaneously monitor the SVs and other quality attributes in the early bioprocess development of ofatumumab, and a sequence variant (SV) was detected by a subunit-based MAM. Subsequently, the variant was further identified by MS/MS and confirmed by adding a synthetic peptide. Furthermore, the content of the SV was detected via DNA sequencing. The levels of the variant (T175A mutant) in the light chain were demonstrate to be nearly consistent at the DNA and protein levels, suggesting that the mutation may have negligible effect on both the transcriptional and translational levels. Collectively, these results indicate that broad-spectrum, rapid, and accurate platform such as MS-based MAM should be implemented to quality control for the early development of therapeutic proteins, it will also be important to establish an effective and integrated MAM to control SVs during therapeutic proteins development.
Collapse
|
31
|
Matte A. Recent Advances and Future Directions in Downstream Processing of Therapeutic Antibodies. Int J Mol Sci 2022; 23:ijms23158663. [PMID: 35955796 PMCID: PMC9369434 DOI: 10.3390/ijms23158663] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2022] [Revised: 08/01/2022] [Accepted: 08/02/2022] [Indexed: 02/05/2023] Open
Abstract
Despite the advent of many new therapies, therapeutic monoclonal antibodies remain a prominent biologics product, with a market value of billions of dollars annually. A variety of downstream processing technological advances have led to a paradigm shift in how therapeutic antibodies are developed and manufactured. A key driver of change has been the increased adoption of single-use technologies for process development and manufacturing. An early-stage developability assessment of potential lead antibodies, using both in silico and high-throughput experimental approaches, is critical to de-risk development and identify molecules amenable to manufacturing. Both statistical and mechanistic modelling approaches are being increasingly applied to downstream process development, allowing for deeper process understanding of chromatographic unit operations. Given the greater adoption of perfusion processes for antibody production, continuous and semi-continuous downstream processes are being increasingly explored as alternatives to batch processes. As part of the Quality by Design (QbD) paradigm, ever more sophisticated process analytical technologies play a key role in understanding antibody product quality in real-time. We should expect that computational prediction and modelling approaches will continue to be advanced and exploited, given the increasing sophistication and robustness of predictive methods compared to the costs, time, and resources required for experimental studies.
Collapse
Affiliation(s)
- Allan Matte
- Downstream Processing Team, Bioprocess Engineering Department, Human Health Therapeutics Research Center, National Research Council Canada, 6100 Royalmount Avenue, Montreal, QC H4P 2R2, Canada
| |
Collapse
|
32
|
Gurel B, Berksoz M, Capkin E, Parlar A, Pala MC, Ozkan A, Capan Y, Daglikoca DE, Yuce M. Structural and Functional Analysis of CEX Fractions Collected from a Novel Avastin® Biosimilar Candidate and Its Innovator: A Comparative Study. Pharmaceutics 2022; 14:pharmaceutics14081571. [PMID: 36015197 PMCID: PMC9415858 DOI: 10.3390/pharmaceutics14081571] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2022] [Revised: 07/25/2022] [Accepted: 07/25/2022] [Indexed: 02/01/2023] Open
Abstract
Avastin® is a humanized recombinant monoclonal antibody used to treat cancer by targeting VEGF-A to inhibit angiogenesis. SIMAB054, an Avastin® biosimilar candidate developed in this study, showed a different charge variant profile than its innovator. Thus, it is fractionated into acidic, main, and basic isoforms and collected physically by Cation Exchange Chromatography (CEX) for a comprehensive structural and functional analysis. The innovator product, fractionated into the same species and collected by the same method, is used as a reference for comparative analysis. Ultra-Performance Liquid Chromatography (UPLC) ESI-QToF was used to analyze the modifications leading to charge heterogeneities at intact protein and peptide levels. The C-terminal lysine clipping and glycosylation profiles of the samples were monitored by intact mAb analysis. The post-translational modifications, including oxidation, deamidation, and N-terminal pyroglutamic acid formation, were determined by peptide mapping analysis in the selected signal peptides. The relative binding affinities of the fractionated charge isoforms against the antigen, VEGF-A, and the neonatal receptor, FcRn, were revealed by Surface Plasmon Resonance (SPR) studies. The results show that all CEX fractions from the innovator product and the SIMAB054 shared the same structural variants, albeit in different ratios. Common glycoforms and post-translational modifications were the same, but at different percentages for some samples. The dissimilarities were mostly originating from the presence of extra C-term Lysin residues, which are prone to enzymatic degradation in the body, and thus they were previously assessed as clinically irrelevant. Another critical finding was the presence of different glyco proteoforms in different charge species, such as increased galactosylation in the acidic and afucosylation in the basic species. SPR characterization of the isolated charge variants further confirmed that basic species found in the CEX analyses of the biosimilar candidate were also present in the innovator product, although at lower amounts. The charge variants’ in vitro antigen- and neonatal receptor-binding activities varied amongst the samples, which could be further investigated in vivo with a larger sample set to reveal the impact on the pharmacokinetics of drug candidates. Minor structural differences may explain antigen-binding differences in the isolated charge variants, which is a key parameter in a comparability exercise. Consequently, such a biosimilar candidate may not comply with high regulatory standards unless the binding differences observed are justified and demonstrated not to have any clinical impact.
Collapse
Affiliation(s)
- Busra Gurel
- SUNUM Nanotechnology Research and Application Center, Sabanci University, Istanbul 34956, Turkey;
| | - Melike Berksoz
- ILKO ARGEM Biotechnology R&D Center, Istanbul 34906, Turkey; (M.B.); (E.C.); (M.C.P.); (A.O.); (Y.C.)
| | - Eda Capkin
- ILKO ARGEM Biotechnology R&D Center, Istanbul 34906, Turkey; (M.B.); (E.C.); (M.C.P.); (A.O.); (Y.C.)
- Faculty of Engineering and Natural Sciences, Sabanci University, Istanbul 34956, Turkey;
| | - Ayhan Parlar
- Faculty of Engineering and Natural Sciences, Sabanci University, Istanbul 34956, Turkey;
| | - Meltem Corbacioglu Pala
- ILKO ARGEM Biotechnology R&D Center, Istanbul 34906, Turkey; (M.B.); (E.C.); (M.C.P.); (A.O.); (Y.C.)
| | - Aylin Ozkan
- ILKO ARGEM Biotechnology R&D Center, Istanbul 34906, Turkey; (M.B.); (E.C.); (M.C.P.); (A.O.); (Y.C.)
| | - Yılmaz Capan
- ILKO ARGEM Biotechnology R&D Center, Istanbul 34906, Turkey; (M.B.); (E.C.); (M.C.P.); (A.O.); (Y.C.)
| | - Duygu Emine Daglikoca
- ILKO ARGEM Biotechnology R&D Center, Istanbul 34906, Turkey; (M.B.); (E.C.); (M.C.P.); (A.O.); (Y.C.)
- Correspondence: (D.E.D.); (M.Y.)
| | - Meral Yuce
- SUNUM Nanotechnology Research and Application Center, Sabanci University, Istanbul 34956, Turkey;
- Correspondence: (D.E.D.); (M.Y.)
| |
Collapse
|
33
|
Li X, Rawal B, Rivera S, Letarte S, Richardson DD. Improvements on sample preparation and peptide separation for reduced peptide mapping based multi-attribute method analysis of therapeutic monoclonal antibodies using lysyl endopeptidase digestion. J Chromatogr A 2022; 1675:463161. [DOI: 10.1016/j.chroma.2022.463161] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2022] [Revised: 05/17/2022] [Accepted: 05/18/2022] [Indexed: 12/14/2022]
|
34
|
Libert BP, Godinho JM, Foster SW, Grinias JP, Boyes BE. Implementing 1.5 mm internal diameter columns into analytical workflows. J Chromatogr A 2022; 1676:463207. [PMID: 35732094 DOI: 10.1016/j.chroma.2022.463207] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2022] [Revised: 06/02/2022] [Accepted: 06/07/2022] [Indexed: 11/25/2022]
Abstract
The use of smaller column diameters in liquid chromatography (LC) is often associated with capillary LC. Although there are many analytical benefits gained by adapting this format, routine use continues to be challenging due to column fragility and extra column dispersion. Bridging the gap between routinely used 2.1 mm columns and capillary bore columns allows for a sequential but far from insignificant increase in performance without the need for specialized equipment associated with very low dispersion LC systems. Moreover, an incremental decrease in column internal diameter (i.d.) allows for similar mass load (avoiding column overload that may be observed in much larger decreases in i.d. without trapping) and thus an increase in measured signal. As such, 1.5 mm i.d. columns provide an alternative intermediate dimension between the more regularly used 2.1 mm i.d. columns and 1 mm i.d. columns. These columns balance an increase in sensitivity compared to 2.1 mm i.d. columns (theoretically doubling the time-domain peak area in mass sensitive detectors for the same mass load), while mitigating the efficiency losses due to extra-column dispersion effects that are commonly observed with 1.0 mm i.d. columns. Here, the use of 1.5 mm i.d. columns was applied to LC/UV analysis of small molecules and LC/MS methods for the analysis of monoclonal antibodies. With equivalent mass load on column, the 1.5 mm i.d. columns provide two-to-threefold improvement in analyte peak area signal for small molecules as well as intact, subunit, and peptide levels of antibody analysis. Peak height was also increased using the 1.5 mm i.d. column, although the scale of increase varies between isocratic and gradient modes, likely due to differences in system dispersion effects and variation in electrospray ionization efficiency at different flow rates.
Collapse
Affiliation(s)
- Benjamin P Libert
- Advanced Materials Technology, Inc., 3521 Silverside Road, Wilmington, DE 19810, USA; Department of Chemistry & Biochemistry, Rowan University, 201 Mullica Hill Rd., Glassboro, NJ 08028, USA
| | - Justin M Godinho
- Advanced Materials Technology, Inc., 3521 Silverside Road, Wilmington, DE 19810, USA
| | - Samuel W Foster
- Department of Chemistry & Biochemistry, Rowan University, 201 Mullica Hill Rd., Glassboro, NJ 08028, USA
| | - James P Grinias
- Department of Chemistry & Biochemistry, Rowan University, 201 Mullica Hill Rd., Glassboro, NJ 08028, USA.
| | - Barry E Boyes
- Advanced Materials Technology, Inc., 3521 Silverside Road, Wilmington, DE 19810, USA.
| |
Collapse
|
35
|
Optimized Methods for Analytical and Functional Comparison of Biosimilar mAb Drugs: A Case Study for Avastin, Mvasi, and Zirabev. Sci Pharm 2022. [DOI: 10.3390/scipharm90020036] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
Bevacizumab is a humanized therapeutic monoclonal antibody used to reduce angiogenesis, a hallmark of cancer, by binding to VEGF-A. Many pharmaceutical companies have developed biosimilars of Bevacizumab in the last decade. The official reports provided by the FDA and EMA summarize the analytical performance of biosimilars as compared to the originators without giving detailed analytical procedures. In the current study, several key methods were optimized and reported for analytical and functional comparison of bevacizumab originators (Avastin, Altuzan) and approved commercial biosimilars (Zirabev and Mvasi). This case study presents a comparative analysis of a set of biosimilars under optimized analytical conditions for the first time in the literature. The chemical structure of all products was analyzed at intact protein and peptide levels by high-resolution mass spectrometry; the major glycoforms and posttranslational modifications, including oxidation, deamidation, N-terminal PyroGlu addition, and C-terminal Lys clipping, were compared. The SPR technique was used to reveal antigen and some receptor binding kinetics of all products, and the ELISA technique was used for C1q binding affinity analysis. Finally, the inhibition performance of the samples was evaluated by an MTS-based proliferation assay in vitro. Major glycoforms were similar, with minor differences among the samples. Posttranslational modifications, except C-terminal Lys, were determined similarly, while unclipped Lys percentage was higher in Zirabev. The binding kinetics for VEGF, FcRn, FcγRIa, and C1q were similar or in the value range of originators. The anti-proliferative effect of Zirabev was slightly higher than the originators and Mvasi. The analysis of biosimilars under the same conditions could provide a new aspect to the literature in terms of the applied analytical techniques. Further studies in this field would be helpful to better understand the inter-comparability of the biosimilars.
Collapse
|
36
|
Yandrofski K, Mouchahoir T, De Leoz ML, Duewer D, Hudgens JW, Anderson KW, Arbogast L, Delaglio F, Brinson RG, Marino JP, Phinney K, Tarlov M, Schiel JE. Interlaboratory Studies Using the NISTmAb to Advance Biopharmaceutical Structural Analytics. Front Mol Biosci 2022; 9:876780. [PMID: 35601836 PMCID: PMC9117750 DOI: 10.3389/fmolb.2022.876780] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2022] [Accepted: 03/21/2022] [Indexed: 01/18/2023] Open
Abstract
Biopharmaceuticals such as monoclonal antibodies are required to be rigorously characterized using a wide range of analytical methods. Various material properties must be characterized and well controlled to assure that clinically relevant features and critical quality attributes are maintained. A thorough understanding of analytical method performance metrics, particularly emerging methods designed to address measurement gaps, is required to assure methods are appropriate for their intended use in assuring drug safety, stability, and functional activity. To this end, a series of interlaboratory studies have been conducted using NISTmAb, a biopharmaceutical-representative and publicly available monoclonal antibody test material, to report on state-of-the-art method performance, harmonize best practices, and inform on potential gaps in the analytical measurement infrastructure. Reported here is a summary of the study designs, results, and future perspectives revealed from these interlaboratory studies which focused on primary structure, post-translational modifications, and higher order structure measurements currently employed during biopharmaceutical development.
Collapse
Affiliation(s)
- Katharina Yandrofski
- Institute for Bioscience and Biotechnology Research, National Institute of Standards and Technology, Rockville, MD, United States
- *Correspondence: Katharina Yandrofski,
| | - Trina Mouchahoir
- Institute for Bioscience and Biotechnology Research, National Institute of Standards and Technology, Rockville, MD, United States
| | | | - David Duewer
- National Institute of Standards and Technology, Gaithersburg, MD, United States
| | - Jeffrey W. Hudgens
- Institute for Bioscience and Biotechnology Research, National Institute of Standards and Technology, Rockville, MD, United States
| | - Kyle W. Anderson
- Institute for Bioscience and Biotechnology Research, National Institute of Standards and Technology, Rockville, MD, United States
| | - Luke Arbogast
- Institute for Bioscience and Biotechnology Research, National Institute of Standards and Technology, Rockville, MD, United States
| | - Frank Delaglio
- Institute for Bioscience and Biotechnology Research, National Institute of Standards and Technology, Rockville, MD, United States
| | - Robert G. Brinson
- Institute for Bioscience and Biotechnology Research, National Institute of Standards and Technology, Rockville, MD, United States
| | - John P. Marino
- Institute for Bioscience and Biotechnology Research, National Institute of Standards and Technology, Rockville, MD, United States
| | - Karen Phinney
- National Institute of Standards and Technology, Gaithersburg, MD, United States
| | - Michael Tarlov
- National Institute of Standards and Technology, Gaithersburg, MD, United States
| | - John E. Schiel
- Institute for Bioscience and Biotechnology Research, National Institute of Standards and Technology, Rockville, MD, United States
| |
Collapse
|
37
|
Liu T, Xu J, Guo Q, Zhang D, Li J, Qian W, Guo H, Zhou X, Hou S. Identification, Efficacy, and Stability Evaluation of Succinimide Modification With a High Abundance in the Framework Region of Golimumab. Front Chem 2022; 10:826923. [PMID: 35449588 PMCID: PMC9017650 DOI: 10.3389/fchem.2022.826923] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2021] [Accepted: 03/08/2022] [Indexed: 11/24/2022] Open
Abstract
Succinimide (Asu) is the intermediate for asparagine deamidation in therapeutic proteins, and it can be readily hydrolyzed to form aspartate and iso-aspartate residues. Moreover, Asu plays an important role in the protein degradation pathways, asparagine deamidation, and aspartic acid isomerization. Here, Asu modification with a high abundance in the framework region (FR) of golimumab was first reported, the effect of denaturing buffer pH on the Asu modification homeostasis was studied, and the results revealed that it was relatively stable over a pH range of 6.0–7.0 whereas a rapid decrease at pH 8.0. Then, the peptide-based multi-attribute method (MAM) analyses showed that the Asu formation was at Asn 43 in the FR of the heavy chain. Meanwhile, the efficacy [affinity, binding and bioactivity, complement-dependent cytotoxicity (CDC) activity, and antibody-dependent cell-mediated cytotoxicity (ADCC) activity] and stability of the Asu modification of golimumab were evaluated, and the current results demonstrated comparable efficacy and stability between the Asu low- and high-abundance groups. Our findings provide valuable insights into Asu modification and its effect on efficacy and stability, and this study also demonstrates that there is a need to develop a broad-spectrum, rapid, and accurate platform to identify and characterize new peaks in the development of therapeutic proteins, particularly for antibody drugs.
Collapse
Affiliation(s)
- Tao Liu
- Department of Oncology, Huashan Hospital, Fudan University, Shanghai, China
- State Key Laboratory of Antibody Medicine and Targeted Therapy, Shanghai, China
- NMPA Key Laboratory for Quality Control of Therapeutic Monoclonal Antibodies, Shanghai, China
| | - Jin Xu
- State Key Laboratory of Antibody Medicine and Targeted Therapy, Shanghai, China
- NMPA Key Laboratory for Quality Control of Therapeutic Monoclonal Antibodies, Shanghai, China
- School of Pharmaceutical Sciences, Liaocheng University, Liaocheng, China
- Shanghai Zhangjiang Biotechnology Co., Ltd., Shanghai, China
| | - Qingcheng Guo
- Taizhou Mabtech Pharmaceuticals Co., Ltd., Taizhou, China
| | - Dapeng Zhang
- State Key Laboratory of Antibody Medicine and Targeted Therapy, Shanghai, China
- NMPA Key Laboratory for Quality Control of Therapeutic Monoclonal Antibodies, Shanghai, China
- School of Pharmaceutical Sciences, Liaocheng University, Liaocheng, China
| | - Jun Li
- School of Pharmaceutical Sciences, Liaocheng University, Liaocheng, China
| | - Weizhu Qian
- State Key Laboratory of Antibody Medicine and Targeted Therapy, Shanghai, China
- NMPA Key Laboratory for Quality Control of Therapeutic Monoclonal Antibodies, Shanghai, China
- School of Pharmaceutical Sciences, Liaocheng University, Liaocheng, China
| | - Huaizu Guo
- State Key Laboratory of Antibody Medicine and Targeted Therapy, Shanghai, China
- NMPA Key Laboratory for Quality Control of Therapeutic Monoclonal Antibodies, Shanghai, China
- School of Pharmaceutical Sciences, Liaocheng University, Liaocheng, China
- Shanghai Zhangjiang Biotechnology Co., Ltd., Shanghai, China
- *Correspondence: Huaizu Guo, ; Xinli Zhou, ; Sheng Hou,
| | - Xinli Zhou
- Department of Oncology, Huashan Hospital, Fudan University, Shanghai, China
- *Correspondence: Huaizu Guo, ; Xinli Zhou, ; Sheng Hou,
| | - Sheng Hou
- State Key Laboratory of Antibody Medicine and Targeted Therapy, Shanghai, China
- NMPA Key Laboratory for Quality Control of Therapeutic Monoclonal Antibodies, Shanghai, China
- School of Pharmaceutical Sciences, Liaocheng University, Liaocheng, China
- *Correspondence: Huaizu Guo, ; Xinli Zhou, ; Sheng Hou,
| |
Collapse
|
38
|
Candish E, Dykstra A, Polozova A, Ren D, Zhang H. New Aspects in the Integration of MS Technologies in the Biopharmaceutical Industry. LCGC NORTH AMERICA 2022. [DOI: 10.56530/lcgc.na.sn9080m1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
In the past decade, advances in both separations and mass spectrometry (MS) technologies have enabled new, streamlined, and data-rich approaches to monitor product quality attributes and their relationship with process parameters throughout the lifecycle of therapeutic proteins. As we enter a new decade of technology and method development, MS-based approaches utilized in the biopharmaceutical industry are evolving further. In this mini-review, we explore key developments that could inspire and improve the future of therapeutic protein development.
Collapse
|
39
|
Numao E, Yanagisawa K, Hosono M, Yagi Y, Nishimura K, Yamazaki K. Development of a comprehensive approach for performance evaluation of a quantitative multi-attribute method as a quality control method. ANAL SCI 2022; 38:739-747. [PMID: 35297021 DOI: 10.1007/s44211-022-00090-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2021] [Accepted: 01/18/2022] [Indexed: 11/28/2022]
Abstract
The multi-attribute method has been recognized as an elegant quantification tool for post-translational modifications (PTMs) of therapeutic proteins, since it can evaluate several attributes spontaneously and site-specifically. Here, the abundance of PTMs calculated by three different types of formula were compared and there was little difference among the results. For the method evaluation, two different kinds of peptides were used as internal standards (ISs) and one of the IS was used as the "standard peak" to define the signal strength of MS. They are also used for system suitability testing to verify whether the condition or sensitivity of mass spectrometry are high enough to evaluate the minor components by confirming the recovery rate of one IS to the another. This system is beneficial that since we have defined the limit of quantification as a certain ratio to IS, consistent MS intensity is applied as the threshold across all detected peaks.
Collapse
Affiliation(s)
- Eriko Numao
- Bio Process Research and Development Laboratories, Production Division, Kyowa Kirin Co., Ltd., Takasaki, Gunma, 370-0013, Japan.
| | - Kumi Yanagisawa
- Bio Process Research and Development Laboratories, Production Division, Kyowa Kirin Co., Ltd., Takasaki, Gunma, 370-0013, Japan
| | - Mayu Hosono
- Bio Process Research and Development Laboratories, Production Division, Kyowa Kirin Co., Ltd., Takasaki, Gunma, 370-0013, Japan
| | - Yuki Yagi
- Bio Process Research and Development Laboratories, Production Division, Kyowa Kirin Co., Ltd., Takasaki, Gunma, 370-0013, Japan
| | - Koichiro Nishimura
- Bio Process Research and Development Laboratories, Production Division, Kyowa Kirin Co., Ltd., Takasaki, Gunma, 370-0013, Japan
| | - Katsuyoshi Yamazaki
- Bio Process Research and Development Laboratories, Production Division, Kyowa Kirin Co., Ltd., Takasaki, Gunma, 370-0013, Japan
| |
Collapse
|
40
|
Ogata Y, Quizon PM, Nightlinger NS, Sitasuwan P, Snodgrass C, Lee LA, Meyer JD, Rogers RS. Automated multi-attribute method sample preparation using high-throughput buffer exchange tips. RAPID COMMUNICATIONS IN MASS SPECTROMETRY : RCM 2022; 36:e9222. [PMID: 34783086 PMCID: PMC9286584 DOI: 10.1002/rcm.9222] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/01/2021] [Revised: 11/02/2021] [Accepted: 11/07/2021] [Indexed: 05/23/2023]
Abstract
RATIONALE The multi-attribute method (MAM) has become a valuable mass spectrometry (MS)-based tool that can identify and quantify the site-specific product attributes and purity information for biotherapeutics such as monoclonal antibodies (mAbs) and fusion molecules in recent years. As we expand the use of the MAM at various stages of drug development, it is critical to enhance the sample preparation throughput without additional chemical modifications and variability. METHODS In this study, a fully automated MAM sample preparation protocol is presented, where rapid desalting in less than 15 minutes is achieved using miniaturized size-exclusion chromatography columns in pipette tips on an automated liquid handler. The peptide samples were analyzed using an electrospray ionization (ESI) orbitrap mass spectrometer coupled to an ultra-high-performance liquid chromatography (UHPLC) system with a dual column switching system. RESULTS No significant change was observed in product attributes and their quantities compared with manual, low-artifact sample preparation. The sample recovery using the buffer exchange tips was greatly enhanced over the manual spin cartridges while still demonstrating excellent reproducibility for a wide variety of starting sample concentrations. Unlike a plate desalting system, the individual columns provide flexibility in the number of samples prepared at a time and sample locations within plates. CONCLUSIONS This automated protocol enables the preparation of up to 96 samples with less "at-bench" time than the manual preparation of a smaller batch of samples, thereby greatly facilitating support of process development and the use of the MAM in quality control.
Collapse
Affiliation(s)
| | | | | | - Pongkwan Sitasuwan
- Integrated Micro‐Chromatography Systems (IMCS), IrmoSCUSA
- 3M CompanySt. PaulMNUSA
| | - Casey Snodgrass
- Hamilton CompanyRenoNVUSA
- Mammoth BiosciencesSan FranciscoCAUSA
| | - L. Andrew Lee
- Integrated Micro‐Chromatography Systems (IMCS), IrmoSCUSA
| | | | | |
Collapse
|
41
|
Vallejo DD, Kang J, Coghlan J, Ramírez CR, Polasky DA, Kurulugama RT, Fjeldsted JC, Schwendeman AA, Ruotolo BT. Collision-Induced Unfolding Reveals Stability Differences in Infliximab Therapeutics under Native and Heat Stress Conditions. Anal Chem 2021; 93:16166-16174. [PMID: 34808055 DOI: 10.1021/acs.analchem.1c03946] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Ion mobility-mass spectrometry (IM-MS) and collision-induced unfolding (CIU) assays of monoclonal antibody (mAb)-based biotherapeutics have proven sensitive to disulfide bridge structures, glycosylation patterns, and small molecule conjugation levels. Despite promising prior reports detailing the capabilities of IM-MS and CIU to differentiate biosimilars, generic mAb therapeutics, there remain questions surrounding the sensitivity of CIU to mAb structure changes that occur upon stress, the reproducibility of such measurements across IM-MS platforms, and the correlation between CIU and differential scanning calorimetry (DSC) datasets. In this report, we describe a comprehensive IM-MS and CIU dataset acquired for three Infliximabs: Remicade, Inflectra, and Renflexis. We subject each infliximab sample to forced degradation through heat stress and observe broadly similar yet subtly different stability patterns for these three biotherapeutics. We find that CIU is capable of tracking differences in mAb higher-order structure (HOS) imparted during forced heat stress degradation and that DSC is less sensitive to these alterations in comparison. Furthermore, we collected our comprehensive IM-MS and CIU data across two instrument platforms (Waters G2 and Agilent 6560), with both producing similar abilities to differentiate mAbs while also revealing minor differences between the results obtained on the two instruments. Finally, we demonstrate that CIU-based heatmaps and classification allow for rapid assessment of the most differentiating charge states for the analysis of infliximab, and using multiplexed classification, we conservatively estimate a 30-fold improvement in the time required to perform mAb stability and HOS measurements over standard DSC tools.
Collapse
Affiliation(s)
- Daniel D Vallejo
- Department of Chemistry, University of Michigan, Ann Arbor, Michigan 48109, United States
| | - Jukyung Kang
- Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, Michigan 48109, United States
| | - Jill Coghlan
- Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, Michigan 48109, United States
| | - Carolina Rojas Ramírez
- Department of Chemistry, University of Michigan, Ann Arbor, Michigan 48109, United States
| | - Daniel A Polasky
- Department of Chemistry, University of Michigan, Ann Arbor, Michigan 48109, United States
| | | | - John C Fjeldsted
- Agilent Technologies, Santa Clara, California 95051, United States
| | - Anna A Schwendeman
- Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, Michigan 48109, United States
| | - Brandon T Ruotolo
- Department of Chemistry, University of Michigan, Ann Arbor, Michigan 48109, United States
| |
Collapse
|
42
|
Hao Z, Moore B, Ren C, Sadek M, Macchi F, Yang L, Harris J, Yee L, Liu E, Tran V, Ninonuevo M, Chen Y, Yu C. Multi-attribute method performance profile for quality control of monoclonal antibody therapeutics. J Pharm Biomed Anal 2021; 205:114330. [PMID: 34479173 DOI: 10.1016/j.jpba.2021.114330] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2021] [Revised: 08/09/2021] [Accepted: 08/14/2021] [Indexed: 11/25/2022]
Abstract
Multi-attribute method (MAM) using peptide map analysis with high resolution mass spectrometry is increasingly common in product characterization and the identification of critical quality attributes (CQAs) of biotherapeutic proteins. Capable of providing structural information specific to amino acid residues, quantifying relative abundance of product variants or degradants, and detecting profile changes between product lots, a robust MAM can replace multiple traditional methods that generate profile-based information for product release and stability testing. In an effort to provide informative and efficient analytical monitoring for monoclonal antibody (mAb) products, from early development to manufacturing quality control, we describe the desired MAM performance profile and address the major scientific challenges in MAM method validation. Furthermore, to support fast speed investigational product development, we describe a platform method validation strategy and results of an optimized MAM workflow. This strategy is applied to support the use of MAM for multiple mAb products with similar structures and physicochemical properties, requiring minimal product-specific method validation activities. Three mAb products were used to demonstrate MAM performance for common and representative product quality attributes. Method validation design and acceptance criteria were guided by the Analytical Target Profile concept, as well as relevant regulatory guidelines to ensure the method is fit-for-purpose. A comprehensive system suitability control strategy was developed, and reported here, to ensure adequate performance of the method including sample preparation, instrument operation, and data analysis. Our results demonstrated sufficient method performance for the characteristics required for quantitative measurement of product variants and degradants.
Collapse
Affiliation(s)
- Zhiqi Hao
- Analytical Development and Quality Control, 1 DNA Way, Genentech, South San Francisco, USA.
| | - Benjamin Moore
- Analytical Development and Quality Control, 1 DNA Way, Genentech, South San Francisco, USA
| | - Chengfeng Ren
- Analytical Development and Quality Control, 1 DNA Way, Genentech, South San Francisco, USA
| | - Monica Sadek
- Analytical Development and Quality Control, 1 DNA Way, Genentech, South San Francisco, USA
| | - Frank Macchi
- Analytical Development and Quality Control, 1 DNA Way, Genentech, South San Francisco, USA
| | - Lindsay Yang
- Analytical Development and Quality Control, 1 DNA Way, Genentech, South San Francisco, USA
| | - Jack Harris
- Analytical Development and Quality Control, 1 DNA Way, Genentech, South San Francisco, USA
| | - Laura Yee
- Analytical Development and Quality Control, 1 DNA Way, Genentech, South San Francisco, USA
| | - Emily Liu
- Analytical Development and Quality Control, 1 DNA Way, Genentech, South San Francisco, USA
| | - Vanessa Tran
- Analytical Development and Quality Control, 1 DNA Way, Genentech, South San Francisco, USA
| | - Milady Ninonuevo
- Analytical Development and Quality Control, 1 DNA Way, Genentech, South San Francisco, USA
| | - Yan Chen
- Analytical Development and Quality Control, 1 DNA Way, Genentech, South San Francisco, USA
| | - Christopher Yu
- Analytical Development and Quality Control, 1 DNA Way, Genentech, South San Francisco, USA.
| |
Collapse
|
43
|
Tajiri-Tsukada M, Hashii N, Ishii-Watabe A. Establishment of a highly precise multi-attribute method for the characterization and quality control of therapeutic monoclonal antibodies. Bioengineered 2021; 11:984-1000. [PMID: 32942957 PMCID: PMC8291864 DOI: 10.1080/21655979.2020.1814683] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
The multi-attribute method (MAM) has garnered attention as a new quality control method of therapeutic monoclonal antibodies (mAbs). MAM analysis allows multiple relative quantifications of several structural attributes of therapeutic mAbs; however, some issues remain to be addressed in its procedures especially for sample preparation. The goal of this study was to optimize the sample preparation method for MAM analysis of mAbs. Using a model mAb, we compared five sample preparation methods based on sequence coverage, peptide redundancy, missed cleavage and chemical deamidation. It was found that low pH buffer and short digestion time reduced artificial deamidation. The desalting process after carboxymethylation was essential to obtaining high sequence coverage by a short digestion time. The generation of missed cleavage peptides was also improved by using a trypsin/lysyl endopeptidase (Lys-C) mixture. Next, we evaluated the usefulness of our method as a part of MAM analysis. Finally, 17 glycopeptides, 2 deamidated peptides and N- and C-terminal peptides of the heavy chain were successfully monitored with acceptable mass accuracy and coefficient of variation (CV, %) of the relative peak area. On the other hand, 4 oxidated peptides indicated the unavoidable slightly higher inter-assay CV (%) of the peak area ratio due to the instability in the MS sample solution. Collectively, we demonstrated that our method was applicable as an easy and reliable sample preparation method for MAM analysis, and the variation in the relative peak area could be influenced by the modification type rather than by the amount of each peptide.
Collapse
Affiliation(s)
- Michiko Tajiri-Tsukada
- Division of Biological Chemistry and Biologicals, National Institute of Health Sciences , Kawasaki, Kanagawa, Japan.,Graduate School of Medical Life Science, Yokohama City University , Yokohama, Kanagawa, Japan
| | - Noritaka Hashii
- Division of Biological Chemistry and Biologicals, National Institute of Health Sciences , Kawasaki, Kanagawa, Japan
| | - Akiko Ishii-Watabe
- Division of Biological Chemistry and Biologicals, National Institute of Health Sciences , Kawasaki, Kanagawa, Japan
| |
Collapse
|
44
|
Sitasuwan P, Powers TW, Medwid T, Huang Y, Bare B, Lee LA. Enhancing the multi-attribute method through an automated and high-throughput sample preparation. MAbs 2021; 13:1978131. [PMID: 34586946 PMCID: PMC8489909 DOI: 10.1080/19420862.2021.1978131] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
The multi-attribute method (MAM), a recent advance in the application of liquid chromatography-mass spectrometry within the pharmaceutical industry, enables the simultaneous monitoring of multiple product quality attributes in a single analytical method. While MAM is coupled with automated data processing and reporting, the sample preparation, based on proteolytic peptide mapping, remains cumbersome and low throughput. The standard sample preparation for MAM relies on protein denaturation, reduction, and alkylation prior to proteolytic digestion, but often a desalting step is required to maintain enzymatic activity. While most of the sample preparation can be automated on a standard robotic liquid handling system, a streamlined approach for protein desalting and temperature modulation is required for a viable, fully automated digestion. In this work, for the first time, a complete tip-based MAM sample preparation is automated on a single robotic liquid handling system, leveraging a deck layout that integrates both heating and cooling functionalities. The fully automated method documented herein achieves a high-throughput sample preparation for MAM, while maintaining superior method performance. Abbreviations: MAM: multi-attribute method; PQAs: product quality attributes; CE: capillary electrophoresis; IEX: ion-exchange chromatography; HILIC-FLR: hydrophilic interaction liquid chromatography coupled to a fluorescence detector; RP-LC/UV: reversed-phase liquid chromatography coupled to a UV detector; MS: mass spectrometry; NPD: new peak detection; GdnHCl: guanidine hydrochloride; TIC: total ion current; pAb: polyclonal antibody; IgG: immunoglobulin G; DTT: dithiothreitol; IAA: iodoacetic acid; TFA: trifluoroacetic acid; A280: absorbance at 280 nm wavelength; 96MPH: 96-channel multi-probe head; CPAC: Cold Plate Air Cooled; HHS: Hamilton Heater Shaker; DWP: Deep-Well Plate; PCR: Polymerase Chain Reaction; NTR: Nested Tip Rack; Met: methionine; Trp: tryptophan; N-term pQ: N-terminal glutamine cyclization; Lys: lysine; PAM: peptidylglycine α-amidating monooxygenase; G0F: asialo-, agalacto-, bi-antennary, core substituted with fucose; G1F: asialo-, mono-galactosylated bi-antennary, core substituted with fucose; G2F: asialo-, bi-galactosylated bi-antennary, core substituted with fucose; G0: asialo-, agalacto-, bi-antennary; Man5: oligomannose 5; Man8: oligomannose 8; TriF: asialo-, tri-galactosylated tri-antennary, core substituted with fucose.
Collapse
Affiliation(s)
| | | | | | | | | | - L Andrew Lee
- Integrated Micro-Chromatography Systems, Inc, Irmo, SC, USA
| |
Collapse
|
45
|
Apostol I, Bondarenko PV, Ren D, Semin DJ, Wu CH, Zhang Z, Goudar CT. Enabling development, manufacturing, and regulatory approval of biotherapeutics through advances in mass spectrometry. Curr Opin Biotechnol 2021; 71:206-215. [PMID: 34508981 DOI: 10.1016/j.copbio.2021.08.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2021] [Revised: 07/20/2021] [Accepted: 08/04/2021] [Indexed: 10/20/2022]
Abstract
Rapid technological advances have significantly improved the capability, versatility, and robustness of mass spectrometers which has led to them playing a central role in the development, characterization, and regulatory filings of biopharmaceuticals. Their application spans the entire continuum of drug development, starting with discovery research through product development, characterization, and marketing authorization and continues well into product life cycle management. The scope of application extends beyond traditional protein characterization and includes elements like clone selection, cell culture physiology and bioprocess optimization, investigation support, and process analytical technology. More recently, advances in the MS-based multi-attribute method are enabling the introduction of MS in a cGMP environment for routine release and stability testing. While most applications of MS to date have been for monoclonal antibodies, the successes and learnings should translate to the characterization of next-gen biotherapeutics where modalities like multispecifics could be more prevalent. In this review, we describe the most significant advances in MS and correlate them to the broad spectrum of applications to biotherapeutic development. We anticipate rapid technological improvements to continue that will further accelerate widespread deployment of MS, thereby elevating our overall understanding of product quality and enabling attribute-focused product development.
Collapse
Affiliation(s)
- Izydor Apostol
- Attribute Sciences, Process Development, Amgen Inc., 1 Amgen Center Drive, Thousand Oaks, CA 91320, United States
| | - Pavel V Bondarenko
- Attribute Sciences, Process Development, Amgen Inc., 1 Amgen Center Drive, Thousand Oaks, CA 91320, United States
| | - Da Ren
- Attribute Sciences, Process Development, Amgen Inc., 1 Amgen Center Drive, Thousand Oaks, CA 91320, United States
| | - David J Semin
- Attribute Sciences, Process Development, Amgen Inc., 1 Amgen Center Drive, Thousand Oaks, CA 91320, United States
| | - Chao-Hsiang Wu
- Attribute Sciences, Process Development, Amgen Inc., 1 Amgen Center Drive, Thousand Oaks, CA 91320, United States
| | - Zhongqi Zhang
- Attribute Sciences, Process Development, Amgen Inc., 1 Amgen Center Drive, Thousand Oaks, CA 91320, United States
| | - Chetan T Goudar
- Attribute Sciences, Process Development, Amgen Inc., 1 Amgen Center Drive, Thousand Oaks, CA 91320, United States.
| |
Collapse
|
46
|
Dykstra AB, Flick TG, Lee B, Blue LE, Angell N. Chip-Based Capillary Zone Electrophoresis Mass Spectrometry for Rapid Resolution and Quantitation of Critical Quality Attributes in Protein Biotherapeutics. JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY 2021; 32:1952-1963. [PMID: 33730487 DOI: 10.1021/jasms.0c00424] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
The aspiration of the multi-attribute method (MAM) is to utilize a single mass spectrometry-based method that can measure multiple attributes simultaneously, thus enabling data-driven decisions more quickly and efficiently. However, challenges associated with identifying and quantitating critical quality attributes such as asparagine deamidation and isoaspartic acid using conventional ultrahigh-pressure liquid chromatography (UHPLC) coupled to mass spectrometry have necessitated long gradients to ensure sufficient separation for quantitation. Microfluidic chip-based capillary zone electrophoresis mass spectrometry (CZE-MS) shows potential to enable rapid charge-based separation of peptide mixtures, and this approach was evaluated using multipeptide mixtures of synthetic peptides as well as digested protein therapeutics. In these experiments, repeatability, linearity, and peak-to-peak resolution of several peptide families containing asparagine deamidation and/or isoaspartic acid were demonstrated. In addition, a comparison of peptide map results acquired with both UHPLC-MS and CZE-MS for two enzymatically digested biological therapeutics showed comparable sequence coverage and quantitation results between the two approaches. As MAM becomes increasingly utilized for analysis of biological therapeutics, MS instrument demand will rapidly increase, resulting in a bottleneck. A CZE-based separation shows potential to alleviate this bottleneck by drastically increasing MAM throughput while providing results comparable to those acquired using conventional UHPLC separations.
Collapse
Affiliation(s)
- Andrew B Dykstra
- Department of Attribute Sciences, Amgen, Inc., Thousand Oaks, California 91320, United States
| | - Tawnya G Flick
- Department of Attribute Sciences, Amgen, Inc., Thousand Oaks, California 91320, United States
| | - Burton Lee
- Department of Attribute Sciences, Amgen, Inc., Thousand Oaks, California 91320, United States
| | - Laura E Blue
- Department of Attribute Sciences, Amgen, Inc., Thousand Oaks, California 91320, United States
| | - Nic Angell
- Department of Attribute Sciences, Amgen, Inc., Thousand Oaks, California 91320, United States
| |
Collapse
|
47
|
Haberger M, Heidenreich AK, Hook M, Fichtl J, Lang R, Cymer F, Adibzadeh M, Kuhne F, Wegele H, Reusch D, Bonnington L, Bulau P. Multiattribute Monitoring of Antibody Charge Variants by Cation-Exchange Chromatography Coupled to Native Mass Spectrometry. JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY 2021; 32:2062-2071. [PMID: 33687195 DOI: 10.1021/jasms.0c00446] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
The aim of this study was to characterize the product variants of a therapeutic T-cell bispecific humanized monoclonal antibody (TCB Mab, ∼200 kDa, asymmetric) and to develop an online cation-exchange chromatography native electrospray mass spectrometry method (CEC-UV-MS) for direct TCB Mab charge variant monitoring during bioprocess and formulation development. For the identification and functional evaluation of the diverse and complex TCB Mab charge variants, offline fractionation combined with comprehensive analytical testing was applied. The offline fractionation of abundant product variant peaks enabled identification of coeluting acid charge variants such as asparagine deamidation, primary and secondary Fab glycosylation (with and without sialic acid), and the presence of O-glycosylation in the G4S-linker region. Consequently, a new nonconsensus N-glycosylation motif (N-338-FG) in the heavy chain CDR region was discovered. Functional evaluation by cell-based potency testing demonstrated a clear and negative impact of both asparagine deamidations, whereas the O-glycosylation did not affect the TCB Mab biological activity. We established an online native CEC-UV-MS method, with an ammonium acetate buffer and pH gradient, to directly monitor the TCB Mab charge variants. All abundant chemical degradations and post-translational amino acid modifications already identified by offline fraction experiments and liquid chromatography mass spectrometry peptide mapping could also be monitored by the online CEC-UV-MS method. The herein reported online native CEC-UV-MS methodology represents a complementary or even alternative approach for multiattribute monitoring of biologics, offering multiple benefits, including increased throughput and reduced sample handling and intact protein information in the near-native state.
Collapse
Affiliation(s)
- Markus Haberger
- Pharma Technical Development, Roche Diagnostics GmbH, 82377 Penzberg, Germany
| | | | - Michaela Hook
- Pharma Technical Development, Roche Diagnostics GmbH, 82377 Penzberg, Germany
| | - Jürgen Fichtl
- Pharma Technical Development, Roche Diagnostics GmbH, 82377 Penzberg, Germany
| | - Rainer Lang
- Pharma Technical Development, Roche Diagnostics GmbH, 82377 Penzberg, Germany
| | - Florian Cymer
- Pharma Technical Development, F. Hoffmann-La Roche Ltd., c, 4070 Basel, Switzerland
| | - Mahdi Adibzadeh
- Pharma Technical Development, F. Hoffmann-La Roche Ltd., c, 4070 Basel, Switzerland
| | - Felix Kuhne
- Pharma Technical Development, Roche Diagnostics GmbH, 82377 Penzberg, Germany
| | - Harald Wegele
- Pharma Technical Development, Roche Diagnostics GmbH, 82377 Penzberg, Germany
| | - Dietmar Reusch
- Pharma Technical Development, Roche Diagnostics GmbH, 82377 Penzberg, Germany
| | - Lea Bonnington
- Pharma Technical Development, Roche Diagnostics GmbH, 82377 Penzberg, Germany
| | - Patrick Bulau
- Pharma Technical Development, Roche Diagnostics GmbH, 82377 Penzberg, Germany
| |
Collapse
|
48
|
Jakes C, Millán-Martín S, Carillo S, Scheffler K, Zaborowska I, Bones J. Tracking the Behavior of Monoclonal Antibody Product Quality Attributes Using a Multi-Attribute Method Workflow. JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY 2021; 32:1998-2012. [PMID: 33513021 DOI: 10.1021/jasms.0c00432] [Citation(s) in RCA: 30] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
The multi-attribute method (MAM) is a liquid chromatography-mass spectrometry based method that is used to directly characterize and monitor many product quality attributes and impurities on biotherapeutics, most commonly at the peptide level. It utilizes high-resolution accurate mass spectral data which are analyzed in an automated fashion. MAM is a promising approach that is intended to replace or supplement several conventional assays with a single LC-MS analysis and can be implemented in a Current Good Manufacturing Practice environment. MAM provides accurate site-specific quantitation information on targeted attributes and the nontargeted new peak detection function allows to detect new peaks as impurities, modifications, or sequence variants when comparing to a reference sample. The high resolution MAM workflow was applied here for three independent case studies. First, to monitor the behavior of monoclonal antibody product quality attributes over the course of a 12-day cell culture experiment providing an insight into the behavior and dynamics of product attributes throughout the process. Second, the workflow was applied to test the purity and identity of a product through analysis of samples spiked with host cell proteins. Third, through the comparison of a drug product and a biosimilar with known sequence variants. The three case studies presented here, clearly demonstrate the robustness and accuracy of the MAM workflow that implies suitability for deployment in the regulated environment.
Collapse
Affiliation(s)
- Craig Jakes
- National Institute for Bioprocessing Research and Training, Foster Avenue, Mount Merrion, Co., Dublin, A94 X099 Ireland
- School of Chemical and Bioprocess Engineering, University College Dublin, Belfield, Dublin 4, D04 V1W8, Ireland
| | - Silvia Millán-Martín
- National Institute for Bioprocessing Research and Training, Foster Avenue, Mount Merrion, Co., Dublin, A94 X099 Ireland
| | - Sara Carillo
- National Institute for Bioprocessing Research and Training, Foster Avenue, Mount Merrion, Co., Dublin, A94 X099 Ireland
| | - Kai Scheffler
- Thermo Fisher Scientific, Dornierstrasse 4, 82110 Germering, Germany
| | - Izabela Zaborowska
- National Institute for Bioprocessing Research and Training, Foster Avenue, Mount Merrion, Co., Dublin, A94 X099 Ireland
| | - Jonathan Bones
- National Institute for Bioprocessing Research and Training, Foster Avenue, Mount Merrion, Co., Dublin, A94 X099 Ireland
- School of Chemical and Bioprocess Engineering, University College Dublin, Belfield, Dublin 4, D04 V1W8, Ireland
| |
Collapse
|
49
|
Čaval T, Buettner A, Haberger M, Reusch D, Heck AJ. Discrepancies between High-Resolution Native and Glycopeptide-Centric Mass Spectrometric Approaches: A Case Study into the Glycosylation of Erythropoietin Variants. JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY 2021; 32:2099-2104. [PMID: 33856811 PMCID: PMC8343523 DOI: 10.1021/jasms.1c00060] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/04/2023]
Abstract
Glycosylation represents a critical quality attribute modulating a myriad of physiochemical properties and effector functions of biotherapeutics. Furthermore, a rising landscape of glycosylated biotherapeutics including biosimilars, biobetters, and fusion proteins harboring complicated and dynamic glycosylation profiles requires tailored analytical approaches capable of characterizing their heterogeneous nature. In this work, we perform in-depth evaluation of the glycosylation profiles of three glycoengineered variants of the widely used biotherapeutic erythropoietin. We analyzed these samples in parallel using a glycopeptide-centric liquid chromatography/mass spectrometry approach and high-resolution native mass spectrometry. Although for all of the studied variants the glycopeptide and native mass spectrometry data were in good qualitative agreement, we observed substantial quantitative differences arising from ionization deficiencies and unwanted neutral losses, in particular, for sialylated glycopeptides in the glycoproteomics approach. However, the latter provides direct information about glycosite localization. We conclude that the combined parallel use of native mass spectrometry and bottom-up glycoproteomics offers superior characterization of glycosylated biotherapeutics and thus provides a valuable attribute in the characterization of glycoengineered proteins and other complex biotherapeutics.
Collapse
Affiliation(s)
- Tomislav Čaval
- Biomolecular
Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular
Research and Utrecht Institute for Pharmaceutical Sciences, University of Utrecht, Padualaan 8, Utrecht 3584 CH, The Netherlands
- Netherlands
Proteomics Center, Padualaan
8, Utrecht 3584 CH, The Netherlands
| | - Alexander Buettner
- Pharma
Technical Development, Roche Diagnostics
GmbH, Penzberg 82377, Germany
| | - Markus Haberger
- Pharma
Technical Development, Roche Diagnostics
GmbH, Penzberg 82377, Germany
| | - Dietmar Reusch
- Pharma
Technical Development, Roche Diagnostics
GmbH, Penzberg 82377, Germany
| | - Albert J.R. Heck
- Biomolecular
Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular
Research and Utrecht Institute for Pharmaceutical Sciences, University of Utrecht, Padualaan 8, Utrecht 3584 CH, The Netherlands
- Netherlands
Proteomics Center, Padualaan
8, Utrecht 3584 CH, The Netherlands
| |
Collapse
|
50
|
Lian Z, Wang N, Tian Y, Huang L. Characterization of Synthetic Peptide Therapeutics Using Liquid Chromatography-Mass Spectrometry: Challenges, Solutions, Pitfalls, and Future Perspectives. JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY 2021; 32:1852-1860. [PMID: 34110145 DOI: 10.1021/jasms.0c00479] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
Synthetic peptides represent an important and expanding class of therapeutics. Despite having a relatively small size as compared to monoclonal antibodies and other proteins, synthetic peptides are subject to many complex structural modifications originating from the starting materials, manufacturing process, and storage conditions. Although mass spectrometry has been increasingly used to characterize impurities of synthetic peptides, systematic review of this field is scarce. In this paper, an overview of the impurities in synthetic peptide therapeutics is provided in the context of how the knowledge from detailed characterization of the impurities using liquid chromatography-mass spectrometry (LC-MS) can be used to develop the manufacturing process and control strategy for synthetic peptide therapeutics following the critical quality attribute (CQA)-driven and risk-based approach. The thresholds for identifying and controlling the impurities are discussed based on currently available regulatory guidance. Specific LC-MS techniques for identification of various types of impurities based on their structural characteristics are discussed with the focus on structural isomers and stereoisomers (i.e., peptide epimers). Absolute and relative quantitation methods for the peptide impurities are critiqued. Potential pitfalls in characterization of synthetic peptide therapeutics using LC-MS are discussed. Finally, a systematic LC-MS workflow for characterizing the impurities in synthetic peptide therapeutics is proposed, and future perspectives on applying emerging LC-MS techniques to address the remaining challenges in the development of synthetic peptide therapeutics are presented.
Collapse
Affiliation(s)
- Zhirui Lian
- Bioproducts Research and Development, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, United States
| | - Ning Wang
- Bioproducts Research and Development, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, United States
| | - Yuwei Tian
- Bioproducts Research and Development, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, United States
| | - Lihua Huang
- Bioproducts Research and Development, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, United States
| |
Collapse
|